INDEX TO VOLUME 14

AUTHOR INDEX

A

AARONS, L.J. *see* RHODES, J.C., 409

ABANG, A. *see* GIACOMINI, K.M., 754

ABERQUEZ, R., BOUNHOURE, J.P., COBBS, JNR. B.W., FAXON, D.P., LIEBAU, G., MANCHESTER, J., OAKLEY, C.M. & TAYLOR, S. Response to captopril in congestive heart failure, 201S

ABEYASEKERA, G. *see* BRODIE, M.J., 144P

ABRAMS, W.B. *see* FERGUSON, R.K., 719

ACKERMAN, S. *see* GUSTAFSSON, L.L., 622P

ADAM, K. & OSWALD, I. A comparison of the effects of chlormezanone and nitrazepam on sleep, 57

ADAMS, K.R.H., BABER, B., HALLIDAY, L.D.C., LITTLER, T.R., ORME, M.L.'E. & SIBEON, R. A clinical and pharmacokinetic study of indomethacin in standard and slow release formations, 612P

ADAMS, K.R.H., HALLIDAY, L.D.C., SIBEON, R.G., BABER, N., LITTLER, T. & ORME, M.L.'E. Clinical and pharmacokinetic study of indomethacin in a standard and slow release formation, 286

ADAMSON, H. *see* GUSTAFSSON, L.L., 622P

ADELUSI, S.A., DAWODU, A.H. & SALAKO, L.A. Kinetics of the uptake and elimination of chloroquine in children with malaria, 483

ADITHAN, C. & THANGAM, J. Comparative study of saliva and serum paracetamol levels using a simple spectrophotometric method, 107

AGENÄS, I. *see* WILHOLM, B.-E., 596P

AGUGLIA, F. *see* SANTUCCI, A., 77S

AHUJA, R.C. *see* NELSON, G.I.C., 85P

AKHRAS, F. *see* HOLT, D.W., 586P

ALANEN, T. *see* NEUVONEN, P.J., 598P

ALDHOUS, M.E., ILIOPOULOU, A., JOHNSTON, A. & TURNER, P. The pharmacokinetics of intravenous theophylline and oral erythromycin, alone and in combination, 610P

ALDHOUS, M.E. *see* ILIOPOULOU, A., 495

ALDOUS, S. *see* PETERSON, G.M., 298

ALLAN, R.J. *see* DAWSON, M., 453

ALMÉR, L.-O. *see* MELANDER, A., 579P

ALSINA, J. *see* RABINAD, E., 103S

ALVÁN, G., ÖHMAN, B. & SJÖQVIST, F. Drugline: a new database for evaluated drug information, 597P

ALVÁN, G. *see* WALKER, O., 624P

AMLIE, J.P. *see* PLATOU, E.S., 591

AMOAH, A.G.B., GOULD, B.J. & PARKE, D.V. Single dose perhexiline pharmacokinetics in human volunteers, 623P

ANDERSSON, K.-E., MATTIASSON, A. & SJOGREN, C. Electrically-induced relaxation of the noradrenaline-contracted isolated urethra from rabbit and man, 576P

ANDERSON, P., BONDESSON, U., SYLVÉN, C. & ASTRÖM, H. Pharmacokinetics and effects of verapamil in patients, 578P

ANGUS, R. *see* HOWARTH, P.J., 599P

ANDREASEN, F., BOTKER, H.E. & LORENTZEN, K. *In vitro* studies on the hydrolysis of frusemide in gastrointestinal juices, 306

ANDREASEN, F. *see* BJERREGAARD, P., 577P

ANDREN, L., KARLBERG, B., ÖHMAN, P., SVENSSON, A., ASPLUND, J. & HANSSON, L. Captopril and atenolol combined with hydrochlorothiazide in essential hypertension, 107S

ARANKO, K., MATTILA, M.J. & SEPPALA, T. Development of tolerance and cross-tolerance to the actions of diazepam and lorazepam on psychomotor skills in man, 619P

ARNOLD, J.M.O. & McDEVITT, D.G. A comparison of standardized isoprenaline sensitivity tests, 581P

ARNOLD, J.M.O. & McDEVITT, D.G. Heart rate and blood pressure responses to intravenous infusions of isoprenaline before and after atropine, 128P

ARNDTS, D. *see* HARRON, D.W.G., 148P

ARAUJO, O.E. *see* GOUGH, P.A., 739

ARRANTO, A. *see* LUOMA, P.V., 606P

ARRANTO, A.J. *see* SOTANIEMI, E.A., 607P

ARVELA, P. & JOUNELA, A. Survey of acute intoxication cases during 1979–1982 in Oulu, 597P

ASPLUND, J. *see* ANDREN, L., 107S

ASPLUND, J. *see* KARLBERG, B.E., 133S

ASTROM, H. *see* ANDERSON, P., 578P

ATTWOOD, J. *see* BIRKETT, D.J., 574

AWAN, N., CODY, R., FAXON, D.P., HOLLENBERG, N.K., IKRAM, H., KELLAWAY, G.S.M., KIRCHERZ, E.Z., KOMAJDA, M., LEVINE, T.B., LOSSNITZER, K., OAKLEY, C.M. & PACKER, M. The role of captopril in the treatment of heart failure, 247S

B

BABER, B. *see* ADAMS, K.R.H., 612P

BABER, N. *see* ADAMS, K.R.H, 286

BACK, D.J., BRECKENRIDGE, A.M., MacIVER, M., ORME, M., ROWE, P.H., STAIGER, Ch., THOMAS, E. & TJIA, J. Effects of ampicillin on oral contraceptive steroids in women, 43

BALCEUS, A. *see* RABINAD, E., 103S

BALSANO, F. *see* SANTUCCI, A., 77S

BARALDI, P. *see* RICCI, S., 209S

BARBER, H.E. *see* DART, A.M., 839

BARBER, H.E. *see* STEELE, W.H., 667

BARKER, N.P. *see* NICHOLLS, D.P., 727

BARLOW, J., BELLACEY, H.F., BURKE, E.J., DAHLSTROM, V., DICKSTEIN, K., FITZGERALD, D.J., FRANK, J., GAZES, P.C., KIRCHERTZ, E.Z., OAKLEY, C.M., PACKER, M. & SHAPIRO, R. The outcome of treatment in patients with severe heart failure, 237S

BARLOW, J., KRAMER, B., LEVINE, T.B., LIEBAU, G., OAKLEY, C.M., OEKLERS, W., SELINGER, H., SHARPE, D.N., WALSH, W.F. & WOLFSON, S. Factors determining acute and long-term therapy response to captopril in congestive heart failure, 175S

BARLOW, J.B. *see* STEINGO, L., 203S

BARNABY, P.F. *see* NORRIS, R.M., 29S

BARNETT, D.B., HUDSON, S.A. & McBURNEY, A. Disopyramide and its *N*-monodesalkyl metabolite in breast milk, 310

BARRADAS, M.A., MIKHAILIDIS, A.M., MIKHAILIDIS, D.P. & DANDONA, P. The effects of fenfluramine on *in vitro* platelet aggregation, 466P

BASHIR, A., LEWIS, M.J. & HENDERSON, A.H. Pharmacokinetic studies of various preparations of glyceryl trinitrate, 779P

BAUMANN, P., TINGUELY, D. & SCHOFF, J. Increase of α_1-acid glycoprotein after treatment with amitriptyline, 102

BAYLEY, S., DOBBS, R.J. & ROBINSON, B.F. Nifedipine in the treatment of hypertension; report of a double-blind controlled trial, 509

BAYLIS, E.M. *see* RAE, S.A., 459

BAX, N.D.S. *see* TUCKER, G.T., 743

BEATTIE, T.J. *see* HENDERSON, I.S., 857

BEELEY, L. *see* KENDALL, M.J., 120

BEERMANN, B. *see* WALKER, O., 624P

BEGG, E.J., CHINWAH, P.M., WEBB, C., DAY, R.O. & WADE, D.N. Enhanced metabolism of mexiletine after phenytoin administration, 219

BELLACEY, H.F. *see* BARLOW, J., 237S

BENEDETTI, M.S. *see* ROVEI, V., 769

BENFIELD, G.F.A., PETTENGELL, K.E., & HUNTER, K.R. Once-daily *v* twice daily glipizide in diabetes mellitus, 614P

BENNETT, D. *see* SLEIGHT, P., 37S

BENNETT, T. *see* MACDONALD, I.A., 583P

BERG, K.J., WALSTAD, R.A. & BERGH, K. The pharmacokinetics and diuretic effect of piretanide and bumetanide in chronic renal insufficiency, 595P

BERGDAHL, B. *see* MAGNUSSON, J.O., 284

BERGH, K. *see* BERG, K.J., 595P

BERGQVIST, Y. *see* FRISK-HOLMBERG, M., 624P

BERGSTRAND, R., JOHANSSON, S., VEDIN, A. & WILHELMSSON, C. Comparison of once-a-day and twice-a-day dosage regimens of enalapril in patients with mild hypertension, 136P

BERKIN, K.E. & KERR, J.W. Tiaramide—a new oral drug for the treatment of asthma, 505

BERTILSSON, L., EICHELBAUM, M., MELLSTROM, B., SAWE, J. & SJÖQVIST, F. Metabolism of various drugs in subjects with different debrisoquine and sparteine oxidation phenotypes, 602P

BERTILSSON, L. *see* VON BAHR, C., 603P

BHAMRA, R. *see* HOLT, D.W., 148P

BINS, J.W. & MATTIE, H. Tubular excretion of β-lactam antibodies in healthy volunteers and in cystic fibrosis patients, 611P

BIOLLAZ, J., SCHELLING, J.L., DES COMBES, B.J., BRUNNER, D.B., DESPONDS, G., BRUNNER, H.R., ULM, E.H., HICHENS, M. & GOMEZ, H.J. Enalapril maleate and a lysine analogue (MK 521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system, 363

BIOLLAZ, J. *see* ULM, E.H., 357

BIRGERSSON, C. *see* VON BAHR, C., 603P

BIRKETT, D.J., MINERS, J.O., GALLUS, A., ATTWOOD, J. & WANWIMOLRUK, S. Sylphinpyrazone can inhibit or induce drug metabolism: effects of tolbutamide and theophylline metabolism in man, 574P

BJERREGAARD, P., EGE NIELSEN, C., ANDREASEN, F. & GOTZSCHE, H. Dose, concentrations and effects of amiodarone, 577P

BLACK, A.K., GREAVES, M.W. & HENSBY, C.N. The effect of systemic prednisolone on arachidonic acid and prostaglandin E_2 and $F_{2\alpha}$ levels in human cutaneous inflammation, 395

BLACK, J.L., SALOME, C.M., YAN, K. & SHAW, J. Comparison between airways response to an α-adrenoceptor agonist and histamine in asthmatic and non-asthmatic subjects, 464P

BLASCHKE, T.F. *see* GIACOMINI, K.M., 754

BOCHNER, F. *see* ELLIOT, C.B., 562

BODEMAR, G. *see* JONSSON, K-A., 815

BOEREE, B.H. *see* GELLERT, A.R., 608P

BOERLIN, H.J. *see* HAVELKA, J., 71S

BOETHIUS, G. *see* WIHOLM, B.-E., 596P

BOGENHOFT, C. *see* MAGNUSSON, J.O., 284

BONDESSON, U. *see* ANDERSON, P., 578P

BONFILS, S. *see* MIGNON, M., 187

BOOBIS, A.R., KAHN, G.C., MURRAY, S., BRODIE, M.J. & DAVIES, D.S. Evidence for a common defect in the impaired oxidation of substrates in the debrisoquine oxidation polymorphism, 602P

BOOBIS, A.R. *see* BRODIE, M.J., 144P

BORÉUS, L.O. *see* WALLIN, A., 605P

BORZIO, M. *see* CALDARA, R., 744

BOTKER, H.E. *see* ANDREASEN, F., 306

BOUNHOURE, J.P., KAYANAKIS, J.G., FAUVEL, J.M. & PUEL, J. Beneficial effects of captopril in left ventricular failure in patients with myocardial infarction, 187S

BOUNHOURE, J.P. *see* ABERQUEZ, R., 201S

BOUTHIER, J.E. *see* SIMON, A.Ch., 241

BOYD, E.J.S. & WORMSLEY, K.G. Clinical assessment of antisecretory drugs in man, 15

BRADBROOK, I.D. *see* MORRISON, P.J., 123

BRAY, C. *see* SLEIGHT, P., 37S

BRECKENRIDGE, A.M. *see* BACK, D.J., 43

BRECKER, S.J.D. *see* NICHOLSON, F., 468

BREDESEN, J.E., PIKE, E. & LUNDE, P.K.M. Plasma binding of disopyramide and mono-*N*-dealkyldisopyramide, 673

BREDESEN, J.E. *see* PIKE, E., 574

BRESLIN, D.J., DE GENRING, DICKSTEIN, K., KARLBERG, B.E., REUBI, F.C., SILVERIA MACHADO, F., STUMPE, K.O., TARAZI, R.C., VETTER, W. & WEINBERGER, M. Long-term experience of captopril in the treatment of primary (essential) hypertension, 139S

BRICK, I. *see* DARRAGH, A., 677

BRICK, I. *see* DARRAGH, A., 871

BRODIE, M.J., BOOBIS, A.R., HILLYARD, C.J., ABEYASEKERA, G., STEVENSON, J.C., MacINTYRE, I. & PARK, B.K. Effect of combination therapy with rifampicin and isoniazid in vitamin D metabolism, 144P

BRODIE, M.J. *see* BOOBIS, A.R., 602P

BRODIE, M.J. *see* RAPEPORT, W.G., 619P

BRODIN, L.-A. *see* SCHENCK-GUSTAFSSON, K., 591P
BROWN, A.M. *see* MACDONALD, I.A., 583P
BROWN, C.B. *see* LENNARD, L., 567
BROWN, J.J., COOPER, R.A., GROBECKER, H., KARLBERG, B.E., KIRCHERTZ, E.J., MATERSON, B.J., MEYER, X., MIMRAN, A., OEKLERS, W., OPIE, C.H., SANDERS, C.A., SANTUCCI, A., SILVERIA MACHADO, F., TARAZI, R.C., VAN DETH, R.M. & VETTER, W. Selection of patients for treatment (including side effects of captopril), 113S
BROWN, J.J., FERNANDEZ-CRUZ, A., HIGGINS, J.G., HOLLENBERG, N.K., KARLBERG, B.E., KIRCHERTZ, E.Z., LEWIS, E., MATERSON, B.J., MIMRAN, A., SILVERIA MACHADO, F., SLEIGHT, P., STUMPE, K.O., TARAZI, R.C. & WEINBERGER, M. The role of captopril in the treatment of hypertension, 241S
BRUNDERT, E. *see* OHNHAUS, E.E., 571P
BRUNN, J.N. *see* WALSTAD, R.A., 626P
BRUNNER, D.B. *see* BIOLLAZ, J., 363
BRUNNER, H.R. *see* ULM, E.H., 357
BRYSON, S.M. *see* DERKX, F.H.M., 139P
BRYSON, S.M. *see* ELLIOTT, H.L., 141P
BRYSON, S.M. *see* ELLIOTT, H.L., 588P
BRYSON, S.M. *see* FOTHERINGHAM, G.H., 595P
BRYSON, S.M. *see* KELMAN, A.W., 247
BURKE, C. *see* HASSAN, S., 369
BURKE, E.J. *see* BARLOW, J., 237S
BURNETT, D. *see* ORAM, M., 341
BURNETT, D. *see* WILSON, K., 333
BURNHAM, W.R. Nutritional support of patients with gastrointestinal disease, 315
BUSH, M. *see* HAMILTON, M.J., 791
BUTLAND, R.J.A., PANG, J.A. & GEDDES, D.M. The selectivity of the β-adrenoceptor for ventilation in man, 707P
BUTLER, J., O'BRIEN, M., O'MALLEY, K. & KELLY, J.G. Lymphocyte β-adrenoceptor density and fitness in athletes, 127P
BUTTERS, L. *see* RUBIN, P.C., 279

C

CAIRNS, J.A. *see* KUMANA, C.R., 519
CAIRNS, J.A. *see* KUMANA, C.R., 529
CALDARA, R., RAMPINI, P., PIEPOLI, V. & BORZIO, M. Effect of labetalol, an α- and β-adrenoceptor antagonist, on gastric acid and gastrin secretion in man, 744
CALDWELL, J. & COTGREAVE, I.A. Comparative disposition of theophylline and ethylenediamine given as aminophylline to human volunteers, 610P
CALISSENDORFF, B. *see* CHIANG, W.T., 590P
CAMM, A.J. *see* JOHNSTON, A., 587P
CAMPBELL, B.C. & REID, J.L. High dose prazosin in the control of rebound hypertension following clonidine withdrawal, 578P
CAMPBELL, B.C. *see* ELLIOTT, H.L., 141P
CAMPBELL, W.S. *see* ELLIOTT, H.L., 588P
CARLIER, J. *see* EL ALLAF, D., 431
CASTLE, W.M. *see* NICHOLLS, D.P., 727
CASTRO-PARRA, M. *see* EICHELBAUM, M., 575P
CHIANG, W.T., VON BAHR, C., CALISSENDORFF, B., DAHLQVIST, R., MAGNUSSEON, A., SCHENCK-GUSTAFSSON, K. & VUOROSALO, D. Plasma concentration and effect of disopyramide and its mono-dealkylated metabolite administered to healthy subjects, 590P
CHANG, W.-H. *see* SCHEININ, M., 617P
CHANOINE, F. *see* ROVEI, V., 769
CHAMBERLAIN, D.A. Summary: critical appraisal of present position and practical issues for the future, 63S
CHAPUT DE SAINTONGE, D.M. & HATTERSLEY, L.A. What makes GPs prescribe antibiotics for otitis media, 151P
CHARD, T. *see* LEE, J.N., 551
CHAU, N.P. *see* MIGNON, M., 187
CHEN, S.S. *see* LEE, J.N., 551
CHIARINI, C. *see* STURANI, A., 849
CHINWAH, P.M. *see* BEGG, E.J., 219
CHOW, C.M. *see* JENKINS, C.R., 113
CHURCH, M.K. *see* CUSHLEYM, J., 607P
CLARK, K.L. *see* NICHOLSON, F., 468
CLAROS, N.M. *see* FERNANDEZ-CRUZ, A., 117S
CLEMENTS, J.A. *see* NIMMO, W.S., 144P
CLIFFORD, J.M., DAY, M.D. & ORWIN, J.M. Reversal of clonidine induced miosis by the α_2-adrenoceptor antagonist RX 781094, 99
CLIFFORD, J.M. & HOARE, R.C. The photographic measurement of miosis in volunteers after i.v. buprenorphine and its relation to other pharmacological effects, 621P
COBBS, JNR, B.W. *see* ABERQUEZ, R., 201S
CODY, R. *see* AWAN, N., 247S
COHEN, H.N. *see* WATSON, I.D., 437
COHN, J.N. *see* LEVINE, T.B., 169S
COLLSTE, P. *see* VON BAHR, C., 580P
COOPER, R. *see* STEINER, J.A., 833
COOPER, R.A. *see* BROWN, J.J., 113S
COTGREAVE, I.A. *see* CALDWELL, J., 610P
COX, D.R. Statistical significance tests, 325
COXON, R.J. *see* SHARPE, D.N., 161S
CREAGER, M.A. *see* FAXON, D.P., 179S
CREWE, K. *see* TUCKER, G.T., 743
CROCHELET, L. *see* EL ALLAF, D., 431
CUISINAUD, G., FERRY, N., POZET, N., ZECH, P.Y. & SASSARD, J. Nalidixic acid kinetics in renal insufficiency, 489
CURRY, S.H. *see* GOUGH, P.A., 739
CUSHLEY, M.J., CHURCH, M.K., PAO, G.J-K. & HOLGATE, S.T. Adenosine-induced bronchoconstriction is not caused by enhanced immunological release of mast cell mediators, 607P

D

DAHLQVIST, R. *see* CHIANG, W.T., 590P
DAHLQVIST, R. *see* SCHENCK-GUSTAFSSON, K., 591P
DAHLSTROM, U. & KARLBERG, B.E. Short- and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure, 231S
DAHLSTROM, V. *see* BARLOW, J., 237S
DALE, L.G. *see* WALSTAD, R.A., 626P
DALLMAN, J.J. *see* GOUGH, P.A., 739
DANDONA, P. *see* BARRADAS, M.A., 466
DANESHMEND, T.K., HOMEIDA, M. & ROBERTS, C.J.C. Effect of hepatosplenic schistosomiasis on the pharmacokinetics of metronidazole and labetalol, 152P

DANESHMEND, T.K. & ROBERTS, C.J.C. Influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol, 73
DANESHMEND, T.K. *see* YOUNG, C.J., 152P
DARRAGH, A., LAMBE, R., BRICK, I. & O'BOYLE, C. Antagonism of the central effects of 3-methylclonazepam, 871P
DARRAGH, A., LAMBE, R., KENNY, M., BRICK, I., TAAFE, W. & O'BOYLE, C. Ro 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability, 677
DART, A.M., McHARDY, K. & BARBER, H.E. The effect of propranolol on luteinising hormone and prolactin plasma concentrations in hypertensive women, 839
DAVIES, D.S. *see* BOOBIS, A.R., 602P
DAVIES, H.J. *see* RILEY, A.J., 695
DAWODU, A.H. *see* ADELUSI, S.A., 483
DAWSON, M., ALLAN, R.J. & WATSON, T.R. The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [^{3}H]-mebendazole, 453P
DAY, M.D. *see* CLIFFORD, J.M., 99
DAY, R.O. *see* BEGG, E.J., 219
DE GENRING *see* BRESLIN, D.J., 139S
DELAPIERRE, D. *see* EL ALLAF, D., 431
DE MATTIA, G. *see* SANTUCCI, A., 77S
DEMETRIADES, J. *see* FERGUSON, R.K., 719
DERKX, F.H.M., BRYSON, S.M., KELMAN, A.W. & WHITING B. Justification for routine monitoring of theophylline and digoxin plasma concen rations, 139P
DERKX, F.H.M. *see* MILLAR, J.A., 129P
DERKX, F.H.M. *see* MILLAR, J.A., 347
DE SCHEPPER, P.J. *see* VAN HECKEN, M., 195
DES COMBES, B.J. *see* BIOLLAZ, J., 363
DESPONDS, G. *see* BIOLLAZ, J., 363
DICKSTEIN, K. *see* BARLOW, J., 237S
DICKSTEIN, K. *see* BRESLIN, D.J., 139S
DIXON, P.A., OFORAH, E. & MAKANJUOLA, R. Predictive indices for chlorpromazine therapy in schizophrenics, 273
DOBBS, R.J. *see* BAYLEY, S., 509
DODSON, M.E. & YOUNG, M. Fluctuations in plasma lorazepam levels during the first 6 h after oral administration, 141P
DOMBEY, S.L. *see* HENDERSON, I.S., 857
DOOGAN, D.P. *see* ROBINSON, J.F., 805
DOWELL, P.S., PIERCE, D.M., FRANKLIN, R.A. & ROBSON, P.J. Routes of meptazinol conjugation in the neonate, 750
DOYLE, V. *see* FITZGERALD, D.J., 582P
DRESSE, A. *see* EL ALLAF, D., 431
DROBINSKI, G. *see* KOMAJDA, M., 223S
DRURY, P.L. *see* OATES, N.S., 601P
DUNDEE, J.W. Plasma diazepam and lorazepam concentrations following oral administration, with and without cimetidine, 618P
DUNDEE, J.W. *see* McGOWAN, W.A.W., 207
DYKMAN, J.H.M. *see* ELLIOT, C.B., 562

E

EGENIELSEN, C. *see* BJERREGAARD, P., 577P
EGGERS, R. *see* MINESHITA, S., 613P
EHNHOLM, C. *see* LUOMA, P.V., 606P
EICHELBAUM, M., MUSCH, E., CASTRO-PARRA, M. & VON SASSEN, W. Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism, 575P
EICHELBAUM, M. *see* BERTILSSON, L., 602P
EL ALLAF, D., HENRARD, L., CROCHELET, L., DELAPIERRE, D., CARLIER, J. & DRESSE, A. Pharmacokinetics of mexiletine in renal insufficiency, 431
ELLIOT, C.B., DYKMAN, J.H.M. & BOCHNER, F. Urinary excretion of aspirin, 562
ELLIOTT, H.L., KELMAN, A.W., SUMNER, D.J., BRYSON, S.M., CAMPBELL, B.C., HILLIS, W.S. & WHITING, B. Pharmacodynamic and pharmacokinetic evaluation of the interaction between digoxin and disopyramide, 141P
ELLIOTT, H.L., SUMNER, D.J., BRYSON, S.M., KELMAN, A.W., CAMPBELL, B.C., HILLIS, W.S. & WHITING B. Evaluation of the cardiac effects following acute and steady state disopyramide, 588P
ELLIOTT, H.L. *see* MEREDITH, P.A., 135P
ELLIOTT, H.L. *see* MEREDITH, P.A., 589P
ELLIOTT, H.L. *see* SUMNER, D.J., 128P
EMERY, P. *see* HOLT, D.W., 586P
ENGLISH, J. *see* RAE, S.A., 459
ENGLISH, L., PYCOCK, C.J., ROBERTS, C.J.C., SHORSBREE, E. & TABERNER, P.V. The interactions between ethanol and nitrazepam and temazepam on human psychomotor performance, 620P
ERIKSSON, S.-E. *see* JONSSON, K.-A., 815
ESPOSTI, E.D. *see* STURANI, A., 849
EUGENE, M. *see* KOMAJDA, M., 223S
EVANS, J. *see* KOMAJDA, M., 223S
EVANS, S.J.W. What can we do with the data we throw away? 653
EVANS, S.P. *see* HOWARTH, P.J., 599P

F

FAUVEL, J.M. *see* BOUNHOURE, J.P., 187S
FAXON, D.P., CREAGER, M.A. & HALPERIN, J.L. Regional circulatory response to converting-enzyme inhibition in congestive heart failure, 179S
FAXON, D.P. *see* ABERQUEZ, R., 201S
FAXON, D.P. *see* AWAN, N., 247S
FEDDER, I.L. *see* MOJAVERIAN, P., 809
FEELY, J., NADEAU, J. & WOOD, A.J.J. Food-induced alterations in the systemic clearance of drugs, 599P
FEELY, J., WADE, D., McALLISTER, C.B., WILKINSON, G.R. & ROBERTSON, D.H. Hypotension reduces liver blood flow and the clearance of lignocaine in man, 139P
FEELY, J. & WOOD, A.J.J. Cimetidine-ethanol interaction, 146P
FEELY, M. The effect on seizure control of adjusting plasma phenytoin within the therapeutic range, 627P
FERGUSON, R.K., VLASSES, P.H., KOPLIN, J.R., HOLMES, G.I., HUBER, P., DEMETRIADES, J. & ABRAMS, W.B. Relationships among timolol doses, plasma concentrations and β-adrenoceptor blocking activity, 719P
FERGUSON, R.K. *see* MOJAVERIAN, P., 809
FERNANDEZ-CRUZ, A. JNR., OTERO, M., PINILLA, C.F. & CLAROS, N.M. Captopril in the treatment of mild essential hypertension, 117S
FERNANDEZ-CRUZ, A. *see* BROWN, J.J., 241S

FERRY, N. *see* CUISINAUD, G., 489
FICARA, C. *see* SANTUCCI, A., 77S
FILE, S.E. & LISTER, R.G. Do lorazepam-induced deficits in learning result from impaired rehearsal, reduced motivation or increased sedation, 545
FISH, A. *see* HASSAN, S., 369
FISHER, B.L. *see* JENKINS, C.R., 113
FISKEN, R.A., WILKINSON, R. & HEATH, D.A. The effects of cimetidine on serum calcium and parathyroid hormone levels in primary hyperparathyroidism, 701
FITZGERALD, D.J., DOYLE, V., O'BRIEN, E. & O'MALLEY, K. Reflex cardiac slowing response to isoprenaline, 582P
FITZGERALD, D.J., HORGAN, J., O'BRIEN, E.T., O'CALLAGHAN, W.G. & O'MALLEY, K. Comparison of the acute haemodynamic effects of captopril and hydralazine in refractory heart failure, 133P
FITZGERALD, D.J., O'CALLAGHAN, W.G., O'MALLEY, K., HORGAN, J. & O'BRIEN, E. Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction, 217S
FITZGERALD, D.J. *see* BARLOW, J., 237S
FLAX, H. *see* STEINGO, L., 203S
FORREST, G. *see* RAPEPORT, W.G., 619P
FOTHERINGHAM, G.H., WHITING, B., KELMAN, A.W. & BRYSON, S.M. Evaluation of kinetic parameter estimation from routine clinical pharmacokinetic data, 595P
FOWLER, M.B. *see* HOLT, D.W., 148P
FOX, M. *see* LENNARD, L., 567
FRAME, M.H., O'REILLY, J. & WILLIAMS, S.W. Dose-response evaluation of inhaled terbutaline in moderate and acute asthma: wet nebulisation *v* dry aerosol via a pear-spacer, 611P
FRANK, J. *see* BARLOW, J., 237S
FRANKLIN, R.A. *see* DOWELL, P.S., 750
FREESTONE, S. & RAMSAY, L.E. Effect of β-adrenoceptor blockade on the pressor response to coffee plus smoking, 582P
FREESTONE, S., RAMSAY, L.E. & SILAS, J.H. Controlled trial of frusemide *v* high-dose thiazide in resistant hypertension, 137P
FREESTONE, S., SILAS, J.H., LENNARD, M.S. & RAMSAY, L.E. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing, 713
FREESTONE, S., SILAS, J.H. & RAMSAY, L.E. Sample size for short-term trials of antihypertensive drugs, 265
FREESTONE, S. *see* LENNARD, M.S., 301
FREESTONE, S. *see* LENNARD, M.S., 572P
FREESTONE, S. *see* RAMSAY, L.E., 134P
FREESTONE, S. *see* SILAS, J.H., 133P
FRISK-HOLMBERG, M. & BERGQVIST, Y. Chloroquine (CQ) disposition in man, 624P
FULLER, R.W. & VALLANCE, P.J.T. Atenolol reduces blood pressure and FEV_1 in normal subjects, 445
FURBERG, C. The β-blocker heart attack trial, 3S
FURSE, L. *see* SLEIGHT, P., 37S

G

GABKA, J. & PRICE, R.K.J. Tooth pulp stimulation: a method of determining the analgesic efficacy of meptazinol in man, 104
GALLUS, A. *see* BIRKETT, D.J., 574
GARLE, M. *see* GUSTAFSSON, L.L., 622P
GAZES, P.C. *see* BARLOW, J., 237S
GEARY, G.G. *see* NORRIS, R.M., 29S
GEDDES, D.M. *see* BUTLAND, R.J.A., 707
GEDDES, D.M. *see* GELLERT, A.R., 608P
GELLERT, A.R., RUDD, R.M., STUDDY, P.R., GEDDES, D.M. & BOEREE, B.H. The effects of M & B 22,948, an orally absorbed mast cell stabiliser, on asthma induced by exercise and by histamine, 608P
GENT, M. *see* KUMANA, C.R., 519
GENT, M. *see* KUMANA, C.R., 529
GEORGE, A.J. & WILSON, K.C.M. Maternal β-endorphin/β-lipotrophin immunoreactivity correlates with maternal prolactin in the first post-partum week, 146P
GEORGE, C.F. *see* HOWARTH, P.J., 599P
GIACOMINI, K.M., ABANG, A. & BLASCHKE, T.F. Calculation of drug concentration in plasma after equilibrium dialysis, 754
GLOVER, D.R. *see* ROWLANDS, D.B., 89
GLYNN, C.J. *see* MATHER, L.A., 385
GOLDBERG, A. *see* RAPEPORT, W.G., 619P
GOMEZ, H.J. *see* BIOLLAZ, J., 363
GOMEZ, H.J. *see* ULM, E.H., 357
GÖRANSSON, M. *see* VON BAHR, C., 603P
GORDIN, A. *see* PAASONEN, M.K., 600P
GOTZSCHE, H. *see* BJERREGAARD, P., 577P
GOUGH, P.A., CURRY, S.H., ARAUJO, O.E., ROBINSON, J.D. & DALLMAN, J.J. Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change, 739
GOULD, B.A., HORNUNG, R.S., KIESO, H., MANN, S. & RAFTERY, E.B. The effect of once daily β-adrenoceptor blocker–thiazide diuretic combination on the ambulatory blood pressure, 827P
GOULD, B.A. *see* HORNUNG, R.S., 83
GOULD, B.A. *see* HORNUNG, R.S., 415
GOULD, B.J. *see* AMOAH, A.G.B., 623P
GRAHNÉN, A., JAMESON, S., LOOF, L., TYLLSTROM, J. & LINSTROM, B. Cimetidine kinetics in liver cirrhosis, 604P
GRANT, I.S. *see* NIMMO, W.S., 144P
GREAVES, M.W. *see* BLACK, A.K., 395
GREENBERG, G. Logistics and management of clinical trials, 25
GREENBLATT, D.J. *see* OCHS, H.R., 225
GREMINGER, P. *see* HAVELKA, J., 71S
GROBECKER, H. *see* BROWN, J.J., 113S
GROSGOGEAT, Y. *see* KOMAJDA, M., 223S
GROVE, J., MARESCAUX, C., RUMBACH, L., SCHECHTER, P.J., TELL, G. & WATER, J.-M. Is measurement of free GABA concentrations in human CSF the most appropriate index of brain GABA activity, 616P
GUGLER, R., MULLER-LIEBENAU, B. & SOMOGYI, A. Altered disposition and availability of cimetidine in liver cirrhotic patients, 421
GUNDERT-REMY, U. *see* SCHMIDLIN, O., 799
GUPTA, R.N. *see* KUMANA, C.R., 519
GUPTA, R.N. *see* KUMANA, C.R., 529
GUSTAFSSON, L.L., ACKERMAN, S., ADAMSON, H., GARLE, M., RANE, A. & SCHILDT, B. Disposition of morphine in cerebrospinal fluid (CSF) after epidural administration, 622P
GUSTAFSSON, L.L. *see* WALKER, O., 624P

H

HALLIDAY, L.D.C. *see* ADAMS, K.R.H., 286

HALLIDAY, L.D.C. *see* ADAMS, K.R.H., 612P

HALPERIN, J.L. *see* FAXON, D.P., 179S

HAMER, J. *see* JOHNSTON, A., 587P

HAMER, N.A.J. *see* WEERASURIYA, K., 130P

HAMILTON, M.J., BUSH, M., SMITH, P. & PECK, A.W. The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man, 791P

HAMILTON, M.J., SMITH, P.R. & PECK, A.W. Bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and EEG in healthy volunteers, 153P

HAMILTON, P. *see* WOODHOUSE, K.W., 615P

HAMPTON, J.R. Now you see it, now you don't. Eccentricities and anomalies in the results of β-blocking trials, 51S

HAND, A.E. *see* ULM, E.H., 357

HANSSON, L. *see* ANDREN, L., 107S

HANSTEEN, V. The Norwegian propranolol trial in selected patients, 9S

HARDELL, L.-I., LINDSTROM, B., LONNERHOLM, G. & OSTERMAN, P.O. Pyridostigmine in human breast milk, 565

HARENBERG, J., STAIGER, Ch., de VRIES, J.X., WALTER, E., WEBER, E. & ZIMMERMAN, R. Cimetidine does not increase the anticoagulant effect of phenprocoumon, 292

HARRISON, I.R. *see* McINNES, G.T., 149P

HARRISON, I.R. *see* McINNES, G.T., 449

HARRISON, I.R. *see* McINNES, G.T., 594P

HARRON, D.W.G., ARNDTS, D. & SHANKS, R.G. Pharmacokinetics of alinidine, 148P

HARRON, D.W.G. *see* NICHOLLS, D.P., 131P

HARRON, D.W.G. *see* NICHOLLS, D.P., 727

HARRY, J.D., YOUNG, J. & STRIBLING, D. Effects of ICI 118551 (a β_2-adrenoceptor blocker) on metabolic changes induced by isoprenaline on tachycardia induced by exercise, 584P

HARTLAPP, J. *see* OCHS, H.R., 225

HASSAN, S., MACDOUGALL, I.C., O'GRADY, J. & PICKLES, H. Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans, 97

HASSAN, S. & PICKLES, H. Epoprostenol (prostacyclin, PGI_2) increases apparent liver blood flow, 572P

HASSAN, S., PICKLES, H., FISH, A., BURKE, C., WARRINGTON, S. & O'GRADY, J. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI_2) are unaffected by β-adrenoceptor blockade in man, 369

HATTERSLEY, L.A. *see* CHAPUT DE SAINTONGE, D.M., 151P

HAVELKA, J., BOERLIN, H.J., STUDER, A., GREMINGER, P., TENSCHERT, W., LUESCHER, T., SIEGENTHALER, W., VETTER, W., WALGER, P. & VETTER, H. Long-term experience with captopril in severe hypertension, 71S

HAWKSWORTH, G.M. *see* STEELE, W.H., 667

HEATH, D.A. *see* FISKEN, R.A., 701

HENDERSON, A.H. *see* BASHIR, A., 779

HENDERSON, I.S., BEATTIE, T.J., KENNEDY, A.C. & DOMBEY, S.L. Oral piretanide in chronic renal failure, 857

HENRARD, L. *see* EL ALLAF, D., 431

HENSBY, C.N. *see* BLACK, A.K., 395

HERMANSSON, J. *see* VON BAHR, C., 79

HERMANSSON, J. *see* VON BAHR, C., 580P

HERZOG, P., HOLTERMÜLLER, K.H., KASPER, W., MEINERTZ, T., TRENK, D. & JÄHNCHEN, E. Absorption of mexiletine after treatment with gastric antacids, 746P

HESP, R. *see* WILKINSON, P.R., 282

HICHENS, M. *see* BIOLLAZ, J., 363

HICHENS, M. *see* ULM, E.H., 357

HIGGINS, J.G. *see* BROWN, J.J., 241S

HILLIS, W.S. *see* ELLIOTT, H.L., 141P

HILLIS, W.S. *see* ELLIOTT, H.L., 588P

HILLIS, W.S. *see* STRUTHERS, A.D., 843

HILLYARD, C.J. *see* BRODIE, M.J., 144P

HIRVISALO, E.L. *see* NEUVONEN, P.J., 598P

HOARE, R.C. *see* CLIFFORD, J.M., 621P

HOCKINGS, N., STEVENSON, I.H. & SWIFT, G.C. Hypnotic response in the elderly—single dose effect of chlormethiazole and dichloralphenazone, 142P

HODGSON, H.J.F. Assessment of drug therapy in inflammatory bowel disease, 159

HOLGATE, S.T. *see* CUSHLEY, M.J., 607P

HOLLENBERG, N.K. *see* AWAN, N., 247S

HOLLENBERG, N.K. *see* BROWN, J.J., 241S

HOLMES, G.I. *see* FERGUSON, R.K., 719

HOLT, D.W., BHAMRA, R., THORLEYK, J., FOWLER, M.B. & JACKSON, G. HPLC measurement of atenolol: placental transfer and expression in breast milk, 148P

HOLT, D.W., UPWARD, J.W., EMERY, P., AKHRAS, F. & JACKSON, G. Dosage schedules for the transition from intravenous lignocaine to oral tocainide following acute myocardial infarction, 586P

HOLT, D.W. *see* JOHNSTON, A., 587P

HOLTERMÜLLER, K.H. *see* HERZOG, P., 746

HOMEIDA, M. *see* DANESHMEND, T.K., 152P

HONG, C.Y. & TURNER, P. Influence of lipid solubility on the sperm immobilizing effect of β-adrenoceptor blocking drugs, 269

HONG, C.Y. *see* PENHALL, R.K., 147P

HORGAN, J. *see* FITZGERALD, D.J., 133P

HORGAN, J. *see* FITZGERALD, D.J., 217S

HORNUNG, R.S., GOULD, B.A., KIESO, H. & RAFTERY, E.B. Study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing, 83

HORNUNG, R.S., GOULD, B.A., KIESO, H. & RAFTERY, E.B. The effect of a combination of timolol, hydrochlorothiazide and amiloride on 24 hour blood pressure control using ambulatory intra-arterial monitoring, 415

HORNUNG, R.S. *see* GOULD, B.A., 827

HORTH, C.E. *see* WILSON, K., 333

HOUBEN, H., THIEN, Th., WIJNANDS, G. & VAN 't LAAR, A. Effects of cold exposure on blood pressure, heart rate and forearm blood flow in normotensives during selective and non-selective β-adrenoceptor blockade, 867P

HOUGHTON, G.W., HUNDT, H.K.L., MULLER, F.O. & TEMPLETON, R. Comparison of the pharmacokinetics of metronidazole in man after administration of single doses of benzoylmetronidazole and metronidazole, 201

HOUSTON, J.B. *see* RHODES, J.C., 409

HOUTZAGERS, J.J.R., STREURMAN, O. & REGARDH, C.G. Effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol, 67

HOWARTH, P.J., ANGUS, R., OATES, J., EVANS, S.P., RENWICK, A.G. & GEORGE, C.F. Metabolism of sulphinpyrazone and interactions occurring within the gastrointestinal tract, 599P
HUBER, P. *see* FERGUSON, R.K., 719
HUDSON, S.A. *see* BARNETT, D.B., 310
HUNDT, H.K.L. *see* HOUGHTON, G.W., 201
HUNTER, K.R. *see* BENFIELD, G.F.A., 614P
HUUPPONEN, R. *see* PIHLAJAMAKI, K., 614P
HUTCHINGS, A., MONIE, R.D., SPRAGG, B. & ROUTLEDGE, P.A. A method to prevent the loss of isoniazid and acetylisonazid in human plasma, 145P

I

IDLE, J.E. *see* OATES, N.S., 601P
ILIOPOULOU, A., ALDHOUS, M.E., JOHNSTON, A. & TURNER, P. Pharmacokinetic interaction between theophylline and erythromycin, 495
ILIOPOULOU, A., WARRINGTON, S.J. & TURNER, P. Preliminary study of the haemodynamic effects of nicardipine, a new calcium antagonist in man, 586P
ILIOPOULOU, A. *see* ALDHOUS, M.E., 610P
INGELMO, M. *see* RABINAD, E., 103S
IKRAM, H. *see* AWAN, N., 247S

J

JACK, D.B. *see* KENDALL, M.J., 120
JACKSON, G. *see* HOLT, D.W., 148P
JACKSON, G. *see* HOLT, D.W., 586P
JACKSON, P.R., RAMSAY, L.E. & WAKEFIELD, V. Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia, 257
JÄHNCHEN, E. *see* HERZOG, P., 746
JAMESON, S. *see* GRAHNÉN, A., 604P
JENKINS, C.R., CHOW, C.M., FISHER, B.L. & MARLIN, G.E. Ipratropium bromide and fenoterol by aerosolized solution, 113
JERNTORP, P. *see* MELANDER, A., 579P
JOGESTRAND, T. *see* SCHENCK-GUSTAFSSON, K., 591P
JOHANSSON, S. *see* BERGSTRAND, R., 136P
JOHN, V.A. *see* MORRISON, P.J., 123
JOHNSTON, A., SLÆVIN, M.L., PARKINS, D.A., HOLT, D.W., HAMER, J. & CAMM, A.J. Verapamil administration by inhalation: a preliminary study to assess the possibility of self administration, 587P
JOHNSTON, A. *see* ALDHOUS, M.E., 610P
JOHNSTON, A. *see* ILIOPOULOU, A., 495
JOHNSTON, A. *see* MUHIDDIN, K.A., 588P
JOHNSTON, A.L. *see* KUMANA, C.R., 519
JOHNSTON, A.L. *see* KUMANA, C.R., 529
JOHNSTON, M. *see* KUMANA, C.R., 519
JOHNSTON, M. *see* KUMANA, C.R., 529
JONES, C.J. *see* RITCH, A.E.S., 116
JONSSON, K.-A., ERIKSSON, S.-E., KAGEVI, I., NORLANDER, B., BODEMAR, G. & WALAN, A. Cimetidine but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose, 815
JONSSON, U.E. *see* MAGNUSSON, J.O., 284
JOUNELA, A. *see* ARVELA, P., 597P
JOVER, B. *see* MIMRAN, A., 81S
JULIAN, D.G. Where are we now?, 57S

K

KAGER, L. *see* RÄNE, A., 573P
KAGEVI, I. *see* JONSSON, K.-A., 815
KAHN, G.C. *see* BOOBIS, A.R., 602P
KAMPMANN, J.P., TAGE, L.S., SKOVSTED, L. & HANSEN, J.E.M. β_2-Adrenoceptor agonists and thyroid hormones, 447
KANNISTO, H. *see* NEUVONEN, P.J., 598P
KARLBERG, B.E., ASPLUND, J., WETTRE, S., OHMAN, K.P. & NILSSON, O.R. Long-term experience of captopril in the treatment of primary (essential) hypertension, 133S
KARLBERG, B.E., MIMRAN, A., OEKLERS, W., SILBERBAUER, K., STUMPE, K.O., TARAZI, R.C. & VETTER, W. Inhibition of prostaglandin synthesis and captopril, 95S
KARLBERG, B. *see* ANDREN, L., 107S
KARLBERG, B.E. *see* BRESLIN, D.J., 139S
KARLBERG, B.E. *see* BROWN, J.J., 113S
KARLBERG, B.E. *see* BROWN, J.J., 241S
KARLBERG, B.E. *see* DAHLSTROM, U., 231S
KASPER, W. *see* HERZOG, P., 746
KAYANAKIS, J.G. *see* BOUNHOURE, J.P., 187S
KECHEJIAN, H. The clinical assessment of analgesic drugs, 754
KELLAWAY, G.S.M. *see* AWAN, N., 247S
KELLY, J.G., McGARRY, K., O'MALLEY, K. & O'BRIEN, E.T. Bioavailability of labetalol increases with age, 304
KELLY, J.G., McMILLEN, R. McC. & McDEVITT, D.G. Effects of digoxin on rubidium-86 uptake by erythrocytes from mothers and babies, 140P
KELLY, J.G. *see* BUTLER, J., 127P
KELMAN, A.W., WHITING, B. & BRYSON, S.M. OPT: a package of computer programs for parameter optimization in clinical pharmacokinetics, 247
KELMAN, A.W. *see* DERKX, F.H.M., 139P
KELMAN, A.W., WHITING, B. & STRUTHERS, A.D. Prediction of bronchodilator response to theophylline in chronic bronchitis, 609P
KELMAN, A.W. *see* ELLIOTT, H.L., 141P
KELMAN, A.W. *see* FOTHERINGHAM, G.H., 595P
KELMAN, A.W. *see* MEREDITH, P.A., 135P
KELMAN, A.W. *see* MEREDITH, P.A., 589P
KELMAN, A.W. *see* STRUTHERS, A.D., 132P
KELMAN, A.W. *see* STRUTHERS, A.D., 843
KELMAN, B.C. *see* ELLIOTT, H.L., 588P
KEMP, M.W. *see* THOMPSON, P.J., 463
KENDALL, M.J., QUARTERMAN, C.P., JACK, D.B. & BEELEY, L. Metoprolol pharmacokinetics and the oral contraceptive pill, 120
KENDALL, M.J., WOODS, K.L., WILKINS, M.R. & WORTHINGTON, D.J. Responsiveness to β-adrenergic receptor stimulation: the effects of age are cardioselective, 821P
KENDALL, M.J. *see* SCOTT, D.L., 691
KENNEDY, A.C. *see* HENDERSON, I.S., 857
KENNY, M. *see* DARRAGH, A., 677
KERR, J.W. *see* BERKIN, K.E., 505

KIERULF, P. *see* PIKE, E., 574
KIESO, H. *see* GOULD, B.A., 827
KIESO, H. *see* HORNUNG, R.S., 83
KIESO, H. *see* HORNUNG, R.S., 415
KILPATRICK, C.J. *see* MARTY, J.J., 399
KIRCHERTZ, E.Z. *see* AWAN, N., 247S
KIRCHERTZ, E.Z. *see* BROWN, J.J., 113S
KIRCHERTZ, E.Z. *see* BROWN, J.J., 241S
KIRCHERTZ, E.Z. *see* BARLOW, J., 237S
KIRK, K. *see* SCHEININ, M., 617P
KNOTT, C. & REYNOLDS, F. Humane monitoring of carbamazepine, 627P
KOLLOCH, R. *see* STUMPE, K.O., 121S
KOMAJDA, M., EUGENE, M., EVANS, J., DROBINSKI, G., LAURENCEAU, J.L. & GROSGOGEAT, Y. Long-term treatment of congestive heart failure with captopril, 223S
KOMAJDA, M. *see* AWAN, N., 247S
KOPLIN, J.R. *see* FERGUSON, R.K., 719
KRAMER, B., TOPIC, N. & MASSIE, B. Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure, 143S
KRAMER, B. *see* BARLOW, J., 175S
KRISHNASWAMY, K. *see* RAGHURAM, T.C., 785
KUMANA, C.R., RAMBIHAR, V.S., TANSER, P.H., CAIRNS, J.A., GUPTA, R.N., WILDEMAN, R.A., JOHNSTON, M., JOHNSON, A.L. & GENT, M. A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction, 519
KUMANA, C.R., RAMBIHAR, V.S., WILLIS, K., GUPTA, R.N., TANSER, P.H., CAIRNS, J.A., WILDEMAN, R.A., JOHNSTON, M., JOHNSTON, A.L. & GENT, M. Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction, 529
KUPFERBERG, H.J. *see* PORRO, M.G., 294

L

LAHER, M.S. *see* O'CALLAGHAN, W.G., 135P
LANDMARK, K. *see* PLATOU, E.S., 591P
LAMBE, R. *see* DARRAGH, A., 677
LAMBE, R. *see* DARRAGH, A., 871
LAURENCEAU, J.L. *see* KOMAJDA, M., 223S
LEE, C.L. *see* WALSH, W.F., 153
LEE, J.N., CHEN, S.S., RICHENS, A., MENABAWEY, M. & CHARD, T. Serum protein binding of diazepam in material and foetal serum during pregnancy, 551
LEE, P.S. *see* TAYLOR, S.H., 585P
LEES, L.J. *see* MAUDGAL, D.P., 213
LEGUY, F. *see* MIGNON, M., 187
LENNARD, A. *see* WOODHOUSE, K.W., 615P
LENNARD, L., BROWN, C.B., FOX, M. & MADDOCKS, J.L. Azathioprine dosage schedule and rejection episodes in renal transplant recipients, 567
LENNARD, M.S., SILAS, J.H., FREESTONE, S. & TREVETHICK, J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine, 301
LENNARD, M.S., SILAS, J.H., FREESTONE, S., TUCKER, G.T., RAMSAY, L.E. & WOODS, H.F. Impaired metabolism of metoprolol in poor hydroxylators of debrisoquine, 572P
LENNARD, M.S. *see* FREESTONE, S., 713
LENNARD, M.S. *see* TUCKER, G.T., 743
LEVENSON, J.A. *see* SIMON, A. Ch., 241
LEVINE, T.B. & COHN, J.N. Factors predicting acute and long-term response to captopril therapy in congestive heart failure, 169S
LEVINE, T.B. *see* AWAN, N., 247S
LEVINE, T.B. *see* BARLOW, J., 175S
LEVY, B.Y. *see* SIMON, A. Ch., 241
LEWIS, E. *see* BROWN, J.J., 241S
LEWIS, J.A. β-Blockade after myocardial infarction—a statistical view, 15S
LEWIS, M.J. *see* BASHIR, A., 779
LEWIS, P.J. *see* RITTER, J.M., 379
LIEBAU, G., RIEGGER, A.J.G., SCHANZENBACHER, P. STEILNER, H. & OEHRLEIN, S. Captopril in congestive heart failure, 193S
LIEBAU, G. *see* ABERQUEZ, R., 201S
LIEBAU, G. *see* BARLOW, J., 175S
LIM, T.P. *see* OH, V.M.S., 593P
LINDBERG, R., SALONEN, J.S., LISALO, E. & SYVÄLAHTI, E. Determination of nomifensine in human plasma by high performance liquid chromatography, 617P
LINDSTRÖM, B. *see* GRAHNÉN, A., 604P
LINDSTRÖM, B. *see* HARDELL, L.-I., 565
LINDSTRÖM, B.L. *see* WALKER, O., 624P
LINNOILA, M. *see* SCHEININ, M., 617P
LIPE, S. *see* STEVENS, M.J., 752
LISALO, E. *see* LINDBERG, R., 617P
LISTER, R.G. *see* FILE, S.E., 545
LITTLER, T. *see* ADAMS, K.R.H., 286
LITTLER, T.R. *see* ADAMS, K.R.H., 612P
LITTLER, W.A. *see* ROWLANDS, D.B., 89
LOKKEN, P. *see* SKJELBRED, P., 539
LONNERHOLM, G. *see* HARDELL, L.-I., 565
LÖÖF, L. *see* GRAHNÉN, A., 604P
LORENTZEN, K. *see* ANDREASEN, F., 306
LOSSNITZER, K. *see* AWAN, N., 247S
LOW, R.A. *see* RUBIN, P.C., 279
LEUSCHER, T. *see* HAVELKA, J., 71S
LUNDE, P.K.M. *see* BREDESEN, J.E., 673
LUNDE, P.K.M. *see* PIKE, E., 574P
LUOMA, P.V., SOTANIEMI, E.A., PELKONEN, R.O., SAVOLAINEN, M.J., ARRANTO, A. & EHNHOLM, C. Enzyme-inducers reduce the risk of atherosclerotic vascular disease? 606P

Mc

McAINSH, J. *see* NICHOLLS, D.P., 727
McALLISTER, C.B. *see* FEELY, J., 139P
McALLISTER, W. *see* THOMPSON, P.J., 463
McBURNEY, A. *see* BARNETT, D.B., 310
McDEVITT, D.G. *see* ARNOLD, J.M.C., 128P
McDEVITT, D.G. *see* ARNOLD, J.M.C., 581P
McDEVITT, D.G. *see* KELLY, J.G., 140P
McGARRY, K. *see* KELLY, J.G., 304
McGARRY, K. *see* O'CALLAGHAN, W.G., 135P
McGIBNEY, D. *see* SILKE, B., 576P
McGOWAN, W.A.W. & DUNDEE, J.W. Effect of intravenous cimetidine on the absorption of orally administered diazepam and lorazepam, 207

McHARDY, K. *see* DART, A.M., 839
McINNES, G.T. Amiloride and spironolactone in the fludrocortisone model, 138P
McINNES, G.T., SHELTON, J.R. & HARRISON, I.R. Time courses of urine electrolyte and plasma potassium responses to treatment with metolazone and spironolactone, 149P
McINNES, G.T., SHELTON, J.R., HARRISON, I.R. & PERKINS, R.M. Potassium-sparing potency of prorenonate K relative to spironolactone, 594P
McINNES, G.T., SHELTON, J.R., HARRISON, I.R., PERKINS, R.M. & RIGBY, G.V. Diuretic induced hypokalaemia: relationship to dosage interval and plasma aldosterone, 449
McINNES, G.T. *see* RAPEPORT, W.G., 619P
McINTOSH, S.J. *see* WATSON, I.D., 437
McLEAN, K. *see* MILLAR, J.R., 129P
McLEAN, K. *see* MILLAR, J.R., 347
McLEAN, S. *see* PETERSON, G.M., 298
McMILLEN, R.McC. *see* KELLY, J.G., 140P
McPHERSON, K. *see* STEINER, J.A., 833
McSHARRY, D. *see* MEREDITH, P.A., 589P

M

MACDONALD, I.A., WILCOX, R.G., BENNETT, T. & BROWN, A.M. The acute effects of metoprolol or propranolol on metabolic and cardiorespiratory responses to exercise in hypertensive patients, 583P
MACDOUGALL, I.C. *see* HASSAN, S., 97
MacGREGOR, J. The role of ambulatory physiological techniques in clinical trial of the NSAI drug piroxicam, 154P
MACHADO, F.S. *see* BRESLIN, D.J., 139S
MACHADO, F.S. *see* BROWN, J.J., 113S
MACHADO, F.S. *see* BROWN, J.J., 241S
MacINTYRE, I. *see* BRODIE, M.J., 144P
MacIVER, M. *see* BACK, D.J., 43
MADDOCKS, J.L. *see* LENNARD, L., 567
MAGNUSSON, A. *see* CHIANG, W.T., 590P
MAGNUSSON, J.O., BERGDAHL, B., BOGENTOFT, C. & JONSSON, U.E. Metabolism of digoxin and absorption site, 284
MAKANJUOLA, R. *see* DIXON, P.A., 273
MANCHESTER, J. *see* ABERQUEZ, R., 201S
MANN, S. *see* GOULD, B.A., 827
MARLIN, G.E. *see* JENKINS, C.R., 113
MARESCAUX, C. *see* GROVE, J., 616P
MARSHALL, R.W., WILSON, J.F. & RICHENS, A. Microcomputer technique for the collection and analysis of data from skeletal muscle twitches, 154P
MARSHALL, T. *see* SCOTT, D.L., 691
MARTINEZ, A. *see* RABINAD, E., 103S
MARTY, J.J., KILPATRICK, C.J. & MOULDS, R.F.W. Intradose variation in plasma protein binding of sodium valproate in epileptic patients, 399
MASSIE, B. *see* KRAMER, B., 143S
MATERSON, B.J. *see* BROWN, J.J., 241S
MATERSON, B.J. *see* BROWN, J.J., 113S
MATHER, L.A. & GLYNN, C.J. The minimum effective analgetic blood concentration of pethidine in patients with intractable pain, 385
MATTIASSON, A. *see* ANDERSSON, K.-E., 576P
MATTIE, H. *see* BINS, J.W., 611P
MATTILA, M.J. *see* ARANKO, K., 619P
MATTIOLI, G. *see* RICCI, S., 209S
MAUDGAL, D.P., MAXWELL, J.D., LEES, L.J. & WILD, R.N. Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man, 213
MAURER, W. *see* SCHMIDLIN, O., 799
MAXWELL, J.D. *see* MAUDGAL, D.P., 213
MEINERTZ, T. *see* HERZOG, P., 746
MELANDER, A., JERNTORP, P., ALMÉR, L.-O., ÖHLIN, H. & WAHLIN-BOLL, E. Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush, 579P
MELLSTRÖM, B. *see* BERTILSSON, L., 602P
MELLSTRÖM, B. *see* VON BAHR, C., 603P
MENABAWEY, M. *see* LEE, J.N., 55L
MEREDITH, P.A., ELLIOTT, H.L., KELMAN, A.W. & REID, J.L. Concentration effect modelling of trimazosin and its major metabolite, 135P
MEREDITH, P.A., ELLIOTT, H.L., McSHARRY, D., KELMAN, A.W. & REID, J.L. The pharmacokinetics of endralazine (BQ22708) in essential hypertensives and normal volunteers, 589P
METSÄ-KETELÄ, T. *see* PAASONEN, M.K., 600P
MEYER, X. *see* BROWN, J.J., 113S
MIGNON, M., CHAU, N.P., NGUYEN-PHUOC, B.K., SAVAGE, M., LEGUY, F. & BONFILS, S. Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships, 187
MIKHAILIDIS, A.M. *see* BARRADAS, M.A., 466
MIKHAILIDIS, D.P. *see* BARRADAS, M.A., 466
MILLAR, J.A., DERKX, F.H.M., McLEAN, K. & REID, J.L. Absence of reflex tachycardia during converting enzyme inhibition: evidence against impairment of autonomic reflexes, 129P
MILLAR, J.A., DERKX, F.H.M., McLEAN, K. & REID, J.L. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK 421 (enalapril) and MK 521, 347
MILLAR, K. & STANDEN, P.J. Differences in performance impairment due to brompheniramine maleate as a function of the sustained-release system, 49
MILLINGEN, K.S. *see* PETERSON, G.M., 298
MIMRAN, A. & JOVER, B. Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage, 81S
MIMRAN, A. *see* BROWN, J.J., 113S
MIMRAN, A. *see* KARLBERG, B.E., 95S
MIMRAN, A. *see* BROWN, J.J., 241S
MINERS, J.O. *see* BIRKETT, D.J., 574
MINESHITA, S., EGGERS, R., NITZSCHE, T. & OHNHAUS, E.E. Kinetics and metabolism of phenacetin in phenacetin abusers, 613P
MISIEWICZ, G. *see* TROTMAN, I., 757
MOJAVERIAN, P., FEDDER, I.L., VLASSES, P.H., ROTMENSCH, H.H., ROCCI, JNR., M.L., SWANSON, B.N. & FERGUSON, R.K. Cimetidine does not alter morphine disposition in man, 809P
MONIE, R.D.H., ROCCHICCIOLI, K.N. & WHITE, J.P. Sustained release aminophylline in asthma and its interaction with rimiterol, 110
MONIE, R.D. *see* HUTCHINGS, A., 145P
MOORE, M.R. *see* RAPEPORT, W.G., 619P
MORELAND, T.A., PARK, B.K. & RYLANCE, G.W. Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6β-

hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity, 861P
MORRISON, P.J., ROGERS, H.J., SPECTOR, R.G., BRADBROOK, I.D. & JOHN, V.A. Effect of pirprofen on glibenclamide kinetics and response, 123
MOULDS, R.F.W. *see* MARTY, J.J., 399
MOULDS, R.F.W. *see* STEVENS, M.J., 752
MUHIDDIN, K.A. & JOHNSTON, A. Non-invasive evaluation of the pharmacodynamic effects of flecainide, a new antiarrhythmic agent, 588P
MUHIDDIN, K.A. *see* PENHALL, R.K., 147P
MULLER, F.O. *see* HOUGHTON, G.W., 201
MULLER-LIEBENAU, B. *see* GUGLER, R., 421
MULLIE, A. *see* VAN HECKEN, A.M., 195
MURRAY, S. *see* BOOBIS, A.R., 602P
MUSCH, M. *see* EICHELBAUM, M., 575P
MWALUKO, G. & WEINSHILBOUM, R. α-Methyldopa, α-methyldopamine and α-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase, 231

N

NADEAU, J. *see* FEELY, J., 599P
NELSON, G.I.C., SILKE, B., AHUJA, R.C. & TAYLOR, S.H. Immediate haemodynamic effects of nifedipine during upright exercise in coronary heart disease, 585P
NEUVONEN, P.J., KANNISTO, H., ALANEN, T. & HIRVISALO, E.L. Effect of activated charcoal on the absorption of tolbutamide and valproate in man, 598P
NEWMARK, M.E. *see* PORRO, M.G., 294
NGUYEN-PHUOC, B.K. *see* MIGNON, M., 187
NICHOLLS, D.P., HARRON, D.W.G., McAINSH, J., CASTLE, W.M., BARKER, N.P. & SHANKS, R.G. Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers, 727
NICHOLLS, D.P., HARRON, D.W.G & SHANKS, R.G. Comparative cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man, 131P
NICHOLSON, A.N., SMITH, P.A. & SPENCER, M.B. Antihistamines and visual function: studies on dynamic acuity and the pupillary response to light, 683
NICHOLSON, F., CLARK, K.L., BRECKER, S.J.D. & SMITH, S.A. A pharmacological method for measuring the penetration of topical mydriatic drugs in man, 468
NILSELL, K. *see* VON BAHR, C., 603P
NILSSON, O.R. *see* KARLBERG, B.E., 133S
NIMMO, W.S., GRANT, I.S. & CLEMENTS, J.A. The pharmacokinetics of ketamine in children, 144P
NITZSCHE, T. *see* MINESHITA, S., 613P
NORLANDER, B. *see* JONSSON, K.-A., 815
NORLANDER, R. *see* SCHENCK-GUSTAFSSON, K., 591P
NORRIS, R.M., BARNABY, P.F. & GEARY, G.G. Intravenous β-blockers during unstable angina and threatened infarction, 29S
NUOTTO, E. *see* PAASONEN, M.K., 600P
NYBERG, G. Bopindolol in angina pectoris: circulatory effects at rest, during exercise and after nitroglycerin, 131P
NYBERG, G. & PANFILOV, V. Effects of nitroglycerin ointment on exercise tolerance, heart rate and blood pressure in patients with coronary heart disease, 592P

O

OAKLEY, C.M. Captopril—experience in heart failure—opening remarks, 141S
OAKLEY, C.M. *see* ABERQUEZ, R., 201S
OAKLEY, C.M. *see* AWAN, N., 247S
OAKLEY, C.M. *see* BARLOW, J., 175S
OAKLEY, C.M. *see* BARLOW, J., 237S
OATES, J. *see* HOWARTH, P.J., 599P
OATES, N.S., SHAH, R.P., DRURY, P.L., IDLE, J.E. & SMITH, R.L. Captopril-induced agranulocytosis associated with an impairment of debrisoquine hydroxylation, 601P
O'BOYLE, C. *see* DARRAGH, A., 677
O'BOYLE, C. *see* DARRAGH, A., 871
O'BRIEN, E. *see* FITZGERALD, D.J., 217S
O'BRIEN, E. *see* FITZGERALD, D.J., 582P
O'BRIEN, E.T. *see* FITZGERLAD, D.J., 133P
O'BRIEN, E.T. *see* KELLY, J.G., 304
O'BRIEN, E.T. *see* O'CALLAGHAN, W.G., 135P
O'BRIEN, M. *see* BUTLER, J., 127P
O'CALLAGHAN, W.G., LAHER, M.S., McGARRY, K., O'BRIEN, E.T. & O'MALLEY, K. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients, 135P
O'CALLAGHAN, W.G. *see* FITZGERALD, D.J., 133P
O'CALLAGHAN, W.G. *see* FITZGERALD, D.J., 217S
OCHS, H.R., PABST, J., GREENBLATT, D.J. & HARTLAPP, J. Digotoxin accumulation, 225
OHERLEIN, S. *see* LEIBAU, G., 193S
OEKLERS, W. *see* BARLOW, J., 175S
OEKLERS, W. *see* BROWN, J.J., 113S
OEKLERS, W. *see* KARLBERG, B.E., 95S
OFORAH, E. *see* DIXON, P.A., 273
O'GRADY, J. *see* HASSAN, S., 97
O'GRADY, J. *see* HASSAN, S., 369
O'GRADY, J. *see* PICKLES, H., 177
OH, V.M.S., TAYLOR, E.A. & LIM, T.P. Effects of chlorothiazide, propranolol and frusemide on erythrocyte cation fluxes in essential hypertension, 593P
O'HANRAHAN, M. *see* O'MALLEY, K., 661
ÖHLIN, H. *see* MELANDER, A., 579P
ÖHMAN, B. *see* ALVÁN, G., 597P
ÖHMAN, K.P. *see* KARLBERG, B.E., 133S
ÖHMAN, P. *see* ANDREN, L., 107S
OHNHAUS, E.E. & BRUNDERT, E. The time course of liver microsomal enzyme induction in man, 571P
OHNHAUS, E.E. *see* MINESHITA, S., 613P
OLATUNDE, A. & PRICE-EVANS, D.A. Blood quinidine levels and cardiac effects in white British and Nigerian subjects, 513
OLLERENSHAW, J.D. *see* RAMSAY, L.E., 134P
O'MALLEY, K. & O'HANRAHAN, M. Drug promotion and the doctor, 661
O'MALLEY, K. *see* BUTLER, J., 127P
O'MALLEY, K. *see* FITZGERALD, D.J., 133P
O'MALLEY, K. *see* FITZGERALD, D.J., 217S
O'MALLEY, K. *see* FITZGERALD, D.J., 582P
O'MALLEY, K. *see* KELLY, J.G., 304
O'MALLEY, K. *see* O'CALLAGHAN, W.G., 135P
OPIE, C.H. *see* BROWN, J.J., 113S
ORAM, M., WILSON, K. & BURNETT, D. The influence of oral contraceptives on the metabolism of methaqualone in man, 341
ORAM, M. *see* WILSON, K., 333
ORCHARD, M.A. *see* RITTER, J.M., 379

O'REILLY, J. *see* FRAME, M.H., 611P
ORME, M.L.'E. Clinical pharmacology of oral contraceptive steroids, 31
ORME, M.L.'E. *see* ADAMS, K.R.H., 286
ORME, M.L.'E. *see* ADAMS, K.R.H., 612P
ORME, M. *see* BACK, D.J., 43
ORWIN, J.M. *see* CLIFFORD, J.M., 99
OSTERMAN, P.O. *see* HARDELL, L.-I., 565
OSWALD, I. *see* ADAM, K., 57
OTERO, M.L. *see* FERNANDEZ-CRUZ, A. 117S
OVERLACK, A. *see* STUMPE, K.O., 121S

P

PAASONEN, M.K., NUOTTO, E., GORDIN, A. & METSÄ-KETELÄ, T. Effect of acetylsalicylic acid on thromboxane A_2 and prostacyclin production and platelet aggregation, 600P
PABST, J. *see* OCHS, H.R., 225
PACKER, M. *see* AWAN, N., 247S
PACKER, M. *see* BARLOW, J., 237S
PANFILOV, V. *see* NYBERG, G., 592P
PANG, J.A. *see* BUTLAND, R.J.A., 707
PAO, G.J.-K. *see* CUSHLEY, M.J., 607P
PARK, B.K. Assessment of the drug metabolism capacity of the liver, 631P
PARK, B.K. *see* BRODIE, M.J., 144P
PARK, B.K. *see* MORELAND, T.A., 861
PARK, B.K. *see* RAPEPORT, W.G., 619P
PARKE, D.V. *see* AMOAH, A.G.B., 623P
PARKINS, D.A. *see* JOHNSTON, A., 587P
PATEL, L. *see* WEERASURIYA, K., 130P
PECK, A.W. *see* HAMILTON, M.J., 791
PECK, A.W. *see* HAMILTON, M.J., 153P
PEDEN, N.R. & WORMSLEY, K.G. Effect of cimetidine on gonadal function in man, 565
PEDERSEN, S. Treatment of children with a single dose a day of sustained release theophylline, 290
PELKONEN, R.O. *see* SOTANIEMI, E.A., 607P
PENHALL, R.K., HONG, C.Y. & MUHIDDIN, K.A. Effect of flecainide on human sperm motility, 147P
PERERA, W.N.R. *see* RITCH, A.E.S., 116
PERKINS, R.M. *see* McINNES, G.T., 449
PERKINS, R.M. *see* McINNES, G.T., 594P
PERONNEAU, P.P. *see* SIMON, A.Ch., 241
PETERSON, G.M., McLEAN, S., ALDOUS, S., VON WITT, R.J. & MILLINGEN, K.S. Plasma protein binding of phenytoin in 100 epileptic patients, 298
PETO, R. *see* SLEIGHT, P., 37S
PETTENGELL, K.E. *see* BENFIELD, G.F.A., 614P
PHILLIPS, F.C., RAMSAY, L.E. & TUCKER, G.T. Hydralazine pyruvate in fast and slow acetylators, 150P
PHILLIPS, F.C. *see* RAMSAY, L.E., 134P
PICKLES, H. & O'GRADY, J. Side effects occurring during administration of prostacyclin in man, 177
PICKLES, H. *see* HASSAN, S., 97
PICKLES, H. *see* HASSAN, S., 369
PICKLES, H. *see* HASSAN, S., 572P
PIEPOLI, V. *see* CALDARA, R., 744
PIERCE, D.M. *see* DOWELL, P.S., 750
PIHLAJAMAKI, K. & HUUPPONEN, R. Insulin and glucose responses to salbutamol after carbohydrate loading, 614P
PIHLAJAMAKI, K. *see* SALONEN, J.S., 608P
PIKE, E., KIERULF, P., SKUTERUD, B., BREDESEN, J.E. & LUNDE, P.K.M. The relative importance of albumin, lipoproteins and orosomucoid for serum binding variations of basic, neutral and acidic drugs, 574P
PIKE, E. *see* BREDESEN, J.E., 673
PINILLA, C.F. *see* FERNANDEZ-CRUZ, A., 117S
PLATOU, E.S., REFSUM, H., AMLIE, J.P. & LANDMARK, K. Plasma levels and cardiac electrophysiological effects of melperone in the absence and presence of β-adrenoceptor blockade, 591P
PLEUVRY, B.J. & REDPATH, J.B.S. Ventilatory and cardiovascular effects of BHT933 in volunteers, 559
PLEUVRY, B.J. *see* REDPATH, J.B.S., 555
POCOCK, W.A. *see* STEINGO, L., 203S
PORRO, M.G., KUPFERBERG, H.J., PORTER, R.J., THEODORE, W.H. & NEWMARK, M.E. Phenytoin: an inhibitor and inducer of primidone metabolism in an epileptic patient, 294
PORTER, R.J. *see* PORRO, M.G., 294
POZET, N. *see* CUISINAUD, G., 489
PRICE, R.K.J. *see* GABKA, J., 104
PRICE-EVANS, D.A. *see* OLATUNDE, A., 513
PUEL, J. *see* BOUNHOURE, J.P., 187S
PYCOCK, C.J. *see* ENGLISH, L., 620P

Q

QUARTERMAN, C.P. *see* KENDALL, M.J., 120

R

RABINAD, E., INGELMO, M., MARTINEZ, A., ALSINA, J. & BALCEUS, G. Captopril in essential hypertension, 103S
RAE, S.A., WILLIAMS, I.A., ENGLISH, J. & BAYLIS, E.M. Alteration of plasma prednisolone levels by indomethacin and naproxen, 459P
RAFTERY, E.B. *see* GOULD, B.A., 827
RAFTERY, E.B. *see* HORNUNG, R.S., 83
RAFTERY, E.B. *see* HORNUNG, R.S., 415
RAFTERY, E.B. *see* WILKINSON, P.R., 282
RAGHURAM, T.C. & KRISHNASWAMY, K. Pharmacokinetics and plasma steady state levels of doxycycline in undernutrition, 785P
RAMBIHAR, V.S. *see* KUMANA, C.R. 519
RAMBIHAR, V.S. *see* KUMANA, C.R. 529
RAMPINI, P. *see* CALDARA, R., 744
RAMSAY, L.E., SILAS, J.H., OLLERENSHAW, J.D., TUCKER, G.T., PHILLIPS, F.C. & FREESTONE, S. Acetylator status and hypotensive response to hydralazine, 134P
RAMSAY, L.E. *see* FREESTONE, S., 137P
RAMSAY, L.E. *see* FREESTONE, S., 265
RAMSAY, L.E. *see* FREESTONE, S., 582P
RAMSAY, L.E. *see* FREESTONE, S., 713
RAMSAY, L.E. *see* JACKSON, P.R., 257
RAMSAY, L.E. *see* LENNARD, M.S., 572P
RAMSAY, L.E. *see* SILAS, J.H., 133P
RAMSDALE, D. *see* SLEIGHT, P., 37S

RÄNE, A., SÄWE, J., SVENSSON, J.O. & KAGER, L. Inter- and intraindividual comparison of morphine metabolism *in vitro* and *in vivo* in man, 573P
RANE, A. *see* GUSTAFSSON, L.L., 622P
RANE, A. *see* SÄWE, J., 622P
RAPEPORT, W.G., McINNES, G.T., FORREST, G., THOMPSON, G.G., MOORE, M.R., SMITH, D.A.S., GOLDBERG, A., PARK, B.K. & BRODIE, M.J. Auto- and hetero-induction with carbamezepine in man, 619P
RAWLINS, M.D. *see* WOODHOUSE, K.W., 615P
REDPATH, J.B.S. & PLEUVRY, B.J. Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (±)-glaucine phosphate in human volunteers, 555
REDPATH, J.B.S. *see* PLEUVRY, B.J., 559
REFSUM, H. *see* PLATOU, E.S., 591P
REGARDH, C.G. *see* HOUTZAGERS, J.J.R., 67
REID, J.L. *see* CAMPBELL, B.C., 578P
REID, J.L. *see* MEREDITH, P.A., 135P
REID, J.L. *see* MEREDITH, P.A., 589P
REID, J.L. *see* MILLAR, J.A., 129P
REID, J.L. *see* MILLAR, J.A., 347
REID, J.L. *see* RUBIN, P.C., 279
REID, J.L. *see* SUMNER, D.J., 128P
RELKONEN, R.O. *see* LUOMA, P.V., 606P
RENWICK, A.G. *see* HOWARTH, P.J., 599P
REUBI, F.C. *see* BRESLIN, D.J., 139S
REYNOLDS, F. *see* KNOTT, C., 627P
RHODES, J.C., AARONS, L.J. & HOUSTON, J.B. Interpretation of CO_2 exhalation rate data from demethylation of aminopyrine and its metabolite monomethylaminoantipyrine, 409
RICCI, S., ZANIOL, P., TEGLIO, V., BARALDI, P. & MATTIOLI, G. Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure, 209S
RICHENS, A. *see* LEE, J.N., 551
RICHENS, A. *see* MARSHALL, R.W., 154P
RICHENS, A. *see* TEDESCHI, G., 142P
RIEGGER, A.H.G. *see* LIEBAU, G., 193S
RIGBY, G.V. *see* McINNES, G.T., 449
RILEY, A.J., RILEY, E.J. & DAVIES, H.J. A method for monitoring drug effects on male sexual response: the effect of single dose labetalol, 695
RILEY, A.J. *see* STEINER, J.A. 833
RILEY, E.J. *see* RILEY, A.J., 695
RITCH, A.E.S., PERERA, W.N.R. & JONES, C.J. Pharmacokinetics of azapropazone in the elderly, 116
RITTER, J.M., ORCHARD, M.A. & LEWIS, P.J. Inhibition of vascular epoprostenol (prostacyclin, PGI_2) production *in vitro* by plasma from healthy subjects and patients with severe renal impairment, 379
ROBERTS, C.J.C. *see* DANESHMEND, T.K., 73
ROBERTS, C.J.C. *see* DANESHMEND, T.K., 152P
ROBERTS, C.J.C. *see* ENGLISH, L., 620P
ROBERTS, C.J.C. *see* YOUNG, C.J., 152P
ROBERTSON, D.H. *see* FEELY, J., 139P
ROBINSON, B.F. *see* BAYLEY, S. 509
ROBINSON, J.D. *see* GOUGH, P.A., 739
ROBINSON, J.F. & DOOGAN, D.P. A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers, 805
ROBSON, P.J. *see* DOWELL, P.S., 750
ROCCI, JR. M.L. *see* MOJAVERIAN, P., 809
ROCCHICCIOLI, K.M. *see* MONIE, R.D.H., 110
RODEN, S. *see* SCOTT, D.L., 691
ROGERS, H.J. *see* MORRISON, P.J., 123
ROSE, G. Prophylaxis with β-blockers and the community, 45S
ROSSI, P. *see* SLEIGHT, P., 37S
ROTMENSCH, H.H. *see* MOJAVERIAN, P., 809
ROUTLEDGE, P.A. *see* HUTCHINGS, A., 145P
ROVEI, V., CHANOINE, F. & BENEDETTI, M.S. Pharmacokinetics of theophylline: a dose-range study, 769P
ROWE, P.H. *see* BACK, D.J., 43
ROWLANDS, D.B., GLOVER, D.R., STALLARD, T.J. & LITTLER, W.A. Control of blood pressure and reduction of echo-cardiographically assessed left ventricular mass with once-daily timolol, 89
ROWLAND, M. & TUCKER, G. Symbols in pharmacokinetics, 7
RUBIN, P.C., BUTTERS, L., LOW, R.A. & REID, J.L. Atenolol in the treatment of essential hypertension during pregnancy, 279
RUDD, R.M. *see* GELLERT, A.R., 608P
RUMBACH, L. *see* GROVE, J., 616P
RYLANCE, G.W. *see* MORELAND, T.A., 861

S

SAFAR, M.E. *see* SIMON, A.Ch., 241
SALAKO, L.A. *see* ADELUSI, S.A., 483
SALOME, C.M. *see* BLACK, J.L., 464
SALONEN, J.S., TURTONEN, J. & PIHLAJAMAKI, K. Levels of monomethylxanthines in sera of theophylline treated patients, 608P
SALONEN, J.S. *see* LINDBERG, R., 617P
SANDERS, C.A. *see* BROWN, J.J., 113S
SANTORO, A. *see* STURANI, A., 849
SANTUCCI, A., AGUGLIA, F., DE MATTIA, G., FICARA, C. & BALSANO, F. Long-term captopril treatment in moderate to severe hypertension, 77S
SANTUCCI, A. *see* BROWN, J.J., 113S
SASSARD, J. *see* CUISINAUD, G., 489
SAUVAGE, M. *see* MIGNON, M., 187
SAVOLAINEN, M.J. *see* LUOMA, P.V., 606P
SÄWE, J., RANE, A. & SVENSSON, J.-O. Morphine metabolism in cancer patients is independent of dose and duration of treatment, 622P
SÄWE, J. *see* BERTILSSON, L., 602P
SÄWE, J. *see* RÄNE, A., 573P
SCHANZENBACHER, P. *see* LEIBAU, G., 193S
SCHECHTER, P.J. *see* GROVE, J., 616P
SCHEINEN, M., CHANG, W.-H., KIRK, K. & LINNOILA, M. H.p.l.c. of monoamine metabolites (MHPG, 5-HIAA and HVA) in CSF and plasma, 617P
SCHELLING, J.L. *see* BIOLLAZ, J., 363
SCHELLING, J.L. *see* ULM, E.H., 357
SCHENCK-GUSTAFSSON, K., JOGESTRAND, T., BRODIN, L.-A., NORLANDER, R. & DAHLQVIST, R. Cardiac effects at steady state during combined treatment with quinidine and digoxin, 591P
SCHENCK-GUSTAFSSON, K. *see* CHIANG, W.T., 590P
SCHILDT, B. *see* GUSTAFSSON, L.L., 622P
SCHMIDLIN, O., GUNDERT-REMY, U., MÄURER, W. &

WEBER, E. Differences of sympathomimetic and anticholinergic action of OH-maprotiline and its R (−)-enantiomer, 799
SCHOFF, J. *see* BAUMANN, P., 102
SCHREYER, S. *see* STUMPE, K.O., 121S
SCOTT, D.L., RODEN, S., MARSHALL, T. & KENDALL, M.J. Variations in responses to non-steroidal anti-inflammatory drugs, 691
SELINGER, H. *see* BARLOW, J., 175S
SELVIG, K. Elimination of proxyphylline and its metabolites, 608P
SEPPALA, T. *see* ARANKO, K., 619P
SHAH, R.R. *see* OATES, N.S., 601P
SHANKS, R.G. *see* HARRON, D.W.G., 148P
SHANKS, R.G. *see* NICHOLLS, D.P., 131P
SHANKS, R.G. *see* NICHOLLS, D.P., 727
SHARPE, D.N. & COXON, R.J. Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure, 161S
SHARPE, D.N. *see* BARLOW, J., 175S
SHAPIRO, R. *see* BARLOW, J., 237S
SHAW, J. *see* BLACK, J.L., 464
SHELTON, J.R. *see* McINNES, G.T., 149P
SHELTON, J.R. *see* McINNES, G.T., 449
SHELTON, J.R. *see* McINNES, G.T., 594P
SHENKIN, A. *see* WATSON, I.D., 437
SHORSBREE, E. *see* ENGLISH, L., 620P
SIBEON, R. *see* ADAMS, K.R.H., 612P
SIBEON, R.G. *see* ADAMS, K.R.H., 286
SIEGENTHALER, W. *see* HAVELKA, J., 71S
SILAS, J.H., RAMSAY, L.E. & FREESTONE, S. Hydralazine once daily in hypertension, 133P
SILAS, J.H. *see* FREESTONE, S., 137P
SILAS, J.H. *see* FREESTONE, S., 265
SILAS, J.H. *see* FREESTONE, S., 713
SILAS, J.H. *see* LENNARD, M.S., 301
SILAS, J.H. *see* LENNARD, M.S., 572P
SILAS, J.H. *see* RAMSAY, L.E., 134P
SILBERBAUER, K., STANEK, B. & TEMPL, H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition, 87S
SILBERBAUER, K. *see* KARLBERG, B.E., 95S
SILKE, B., McGIBNEY, D., SINGLETON, W. & TAYLOR, S.H. Hypotension does not explain isoprenaline tachycardia differences between β-adrenoceptor blocking drugs with and without cardioselectivity, 576P
SILKE, B. *see* NELSON, G.I.C., 585P
SILKE, B. *see* TAYLOR, S.H., 585P
SIMON, A.Ch., LEVENSON, J.A., LEVY, B.Y., BOUTHIER, J.E., PERONNEAU, P.P. & SAFAR, M.E. Effect of nitroglycerin on peripheral large arteries in hypertension, 241
SIMON, R. Patient subsets and variation in therapeutic efficacy, 473
SINGLETON, W. *see* SILKE, B., 576P
SJOGREN, C. *see* ANDERSSON, K.-E., 576P
SJÖQVIST, F. *see* ALVÁN, G., 597P
SJÖQVIST, F. *see* BERTILSSON, L., 602P
SJÖQVIST, F. *see* VON BAHR, C., 603P
SJÖQVIST, F. *see* WALKER, O., 624P
SKJELBRED, P. & LOKKEN, P. Codeine added to paracetamol—induced adverse effects but did not increase analgesia, 539
SKUTERUD, B. *see* PIKE, E., 574
SLEIGHT, P., YUSEF, S., RAMSDALE, D., ROSSI, P., PETO, R., BENNETT, D., BRAY, C. & FURSE, L. Early intravenous β-blockade in myocardial infarction, 37S
SLEIGHT, P. *see* BROWN, J.J., 241S
SLEVIN, M.L. *see* JOHNSTON, A., 587P
SMITH, A. *see* RAPEPORT, W.G., 619P
SMITH, A.T. *see* TEDESCHI, G., 142P
SMITH, M.J. *see* HAMILTON, M.J., 153P
SMITH, R.L. *see* OATES, N.S., 601P
SMITH, P. *see* HAMILTON, M.J., 791
SMITH, P.A. *see* NICHOLSON, A.N., 683
SMITH, S.A. *see* NICHOLSON, F., 468
SNELL, E.S. Drug promotion and the doctor—a reply, 664
SOMOGYI, A. *see* GUGLER, R., 421
SOTANIEMI, E.A., SUTINEN, S., SUTINEN, S., ARRANTO, A.J. & PELKONEN, R.O. Hepatic enzyme induction and smooth endoplasmic reticulum (SER) of hepatocytes in man, 607P
SOTANIEMI, E.A. *see* LUOMA, P.V., 606P
SPARKS, M.G. *see* TEDESCHI, G., 142P
SPECTOR, R.G. *see* MORRISON, P.J., 123
SPENCER, M.B. *see* NICHOLSON, A.N., 683
SPICER, C.C. Statistical decision theory and clinical trials, 765P
SPRAGG, B. *see* HUTCHINGS, A., 145P
STAIGER, Ch. *see* BACK, D.J., 43
STAIGER, Ch. *see* HARENBERG, J., 292
STALLARD, T.J. *see* ROWLANDS, D.B., 89
STANDEN, P.J. *see* MILLAR, K., 49
STANEK, B. *see* SILBERBAUER, K., 87S
STEELE, W.H., HAWKSWORTH, G.M. & BARBER, H.E. The binding of prednisolone in human serum and to recrystallised human albumin *in vitro*, 667
STEILNER, H. *see* LEIBAU, G., 193S
STEIN, M. *see* STEINGO, L., 203S
STEINER, E. *see* TAWARA, K., 580P
STEINER, J.A., COOPER, R., McPHERSON, K. & RILEY, A.J. Effect of β-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients, 833
STEINGO, L., POCOCK, W.A., FLAX, H., STEIN, M. & BARLOW, J.B. Long-term captopril therapy in severe refractory congestive heart failure, 203S
STEVENS, M.J., LIPE, S. & MOULDS, R.F.W. The effect of age on the responses of human isolated arteries and veins to noradrenaline, 752
STEVENSON, I.H. *see* HOCKINGS, N., 142P
STEVENSON, J.C. *see* BRODIE, M.J., 144P
STEWART, M.J. *see* WATSON, I.D., 437
STREURMAN, O. *see* HOUTZAGERS, J.J.R., 67
STRIBLING, D. *see* HARRY, J.D., 584P
STRUTHERS, A.D., WHITING, B., HILLIS, W.S. & KELMAN, A.W. The effect of glyceryl trinitrate ointment on heart rate—corrected systolic time intervals in angina pectoris, 843P
STRUTHERS, A.D., WHITING, B. & KELMAN, A.W. Systolic time intervals in myocardial ischaemia: the effect of glyceryl trinitrate ointment, 132P
STRUTHERS, A.D. *see* KELMAN, A.W., 609P
STUDDY, P.R. *see* GELLERT, A.R., 608P
STUDER, A. *see* HAVELKA, J., 71S
STUMPE, K.O., OVERLACK, A., KOLLOCH, R. & SCHREYER, S. Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension, 121S
STUMPE, K.O. *see* BRESLIN, D.J., 139S

STUMPE, K.O. *see* BROWN, J.J., 241S
STUMPE, K.O. *see* KARLBERG, B.E., 95S
STURANI, A., CHIARINI, C., ESPOSTI, E.D., SANTORO, A., ZUCCALA, A. & ZUCCHELLI, P. Heart rate control in hypertensive patients treated by captopril, 849
SUMNER, D.J., ELLIOTT, H.L. & REID, J.L. Analysis of pressor dose-response curves in human subjects, 128P
SUMNER, D.J. *see* ELLIOTT, H.L., 141P
SUMNER, D.J. *see* ELLIOTT, H.L., 588P
SUTINEN, S. *see* SOTANIEMI, E.A., 607P
SVENSSON, A. *see* ANDREN, L., 107S
SVENSSON, J.O. *see* RÄNE, A., 573P
SVENSSON, J.-O. *see* SÄWE, J., 622P
SVENSSON, L. *see* VON BAHR, C., 580P
SWANSON, B.N. *see* MOJAVERIAN, P., 809
SWIFT, G.C. *see* HOCKINGS, N., 142P
SYVÄLAHTI, E. *see* LINDBERG, R., 617P
SYLVEN, C. *see* ANDERSON, P., 578P

T

TAAFFE, W. *see* DARRAGH, A., 677
TABERNER, P.V. *see* ENGLISH, L., 620P
TAIT, C. *see* WILKINSON, P.R., 282
TANSER, P.H. *see* KUMANA, C.R., 519
TANSER, P.H. *see* KUMANA, C.R., 529
TARAZI, R.C. Captopril—experience in hypertension—opening remarks, 69S
TARAZI, R.C. *see* BRESLIN, D.J., 139S
TARAZI, R.C. *see* BROWN, J.J., 113S
TARAZI, R.C. *see* BROWN, J.J., 241S
TARAZI, R.C. *see* KARLBERG, B.E., 95S
TAWARA, K., STEINER, E. & VON BAHR, C. Catecholamine receptors on blood cells and responsiveness to propranolol in man, 580P
TAWARA, K. *see* VON BAHR, C., 79
TAWARA, K. *see* VON BAHR, C., 580P
TAYLOR, E.A. *see* OH, V.M.S., 593P
TAYLOR, S. *see* ABERQUEZ, R., 201S
TAYLOR, S.H., SILKE, B. & LEE, P.S. Influence of ancilliary properties of β-adrenoceptor antagonists on left ventricular function in coronary heart disease, 585P
TAYLOR, S.H. *see* NELSON, G.I.C., 585P
TAYLOR, S.H. *see* SILKE, B., 576P
TEDESCHI, G., SMITH, A.T., SPARKS, M.G. & RICHENS, A. Effect of intravenous diazepam on peak saccadic velocity, 142P
TEGLIO, V. *see* RICCI, S., 209S
TELL, G. *see* GROVE, J., 616P
TEMPL, H. *see* SILBERBAUER, K., 87S
TEMPLETON, R. *see* HOUGHTON, G.W., 201
TENSCHERT, W. *see* HAVELKA, J., 71S
THANGAM, J. *see* ADITHAN, C., 107
THEODORE, W.H. *see* PORRO, M.G., 294
THIEN, Th. *see* HOUBEN, H., 867
THOMAS, E. *see* BACK, D.J., 43
THOMPSON, G.G. *see* RAPEPORT, W.G., 619P
THOMPSON, P.J., KEMP, M.W., McALLISTER, W. & TURNER, M. The use of aminophylline by inhalation, 463P
THOMSON, J.A. *see* WATSON, I.D., 437
THORLEY, K.J. *see* HOLT, D.W., 148P
THURMANN-NIELSEN, E. *see* WALSTAD, R.A., 626P
TILL, H.J. *see* ULM, E.H., 357
TINGUELY, D. *see* BAUMANN, P., 102
TJANDRAMAGA, T.B. *see* VAN HECKEN, A.M., 195
TJIA, J. *see* BACK, D.J., 43
TOIVANEN, J. *see* VIINIKKA, L., 456
TOPIC, N. *see* KRAMER, B., 143S
TRENK, D. *see* HERZOG, P., 746
TREVETHICK, J. *see* LENNARD, M.S., 301
TROTMAN, I. & MISIEWICZ, G. Methods in human alimentary motility, 757P
TUCKER, G. *see* ROWLAND, M., 7
TUCKER, G.T., BAX, N.D.S., LENNARD, M.S., CREWE, K. & WOODS, H.F. Lack of effect of atenolol on antipyrine clearance, 743
TUCKER, G.T. *see* LENNARD, M.S., 572P
TUCKER, G.T. *see* RAMSAY, L.E., 134P
TURNER, P. *see* ALDHOUS, M.E., 610P
TURNER, P. *see* HONG, C.Y., 269
TURNER, P. *see* ILIOPOULOU, A., 495
TURNER, P. *see* ILIOPOULOU, A., 586P
TURNER, W.M. *see* THOMPSON, P.J., 463
TURTONEN, J. *see* SALONEN, J.S., 608P
TYLLSTRÖM, J. *see* GRAHNÉN, A., 604P

U

ULM, E.H., HICHENS, M., GOMEZ, H.J., TILL, A.E., HAND, E., VASSIL, R.C., BIOLLAZ, J., BRUNNER, H.R. & SCHELLING, J.L. Enalapril maleate and a lysine analogue (MK 521): disposition in man, 357
ULM, E.H. *see* BIOLLAZ, J., 363
UPWARD, J.W. *see* HOLT, D.W., 586P
UTINNENE, S. *see* SOTANIEMI, E.A., 607P

V

VALLANCE, P.J.T. *see* FULLER, R.W., 445
VANDENBURG, M.J. The acute and chronic effect of oxprenolol and propranolol on peripheral blood flow in hypertensive patients, 733
VAN DETH, R.M. *see* BROWN, J.J., 113S
VAN HECKEN, A.M., TJANDRAMAGA, T.B., MULLIE, A., VERBESSELT, R. & DE SCHEPPER, P.J. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man, 195
VAN 't LAAR, A. *see* HOUBEN, H., 867
VASSIL, R.C. *see* ULM, E.H., 357
VEDIN, A. *see* BERGSTRAND, R., 136P
VERBESSELT, R. *see* VAN HECKEN, A.M., 195
VERE, D.W. Logic and inference in clinical trials, 171
VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP ON ANTIHYPERTENSIVE AGENTS. Racial differences in response to low dose captopril are abolished by the addition of hydrochlorothiazide, 97S
VETTER, H. *see* HAVELKA, J., 71S
VETTER, W. *see* BRESLIN, D.J., 139S
VETTER, W. *see* BROWN, J.J., 113S
VETTER, W. *see* HAVELKA, J., 71S
VETTER, W. *see* KARLBERG, B.E., 95S

VIINIKKA, L., TOIVANEN, J. & YLIKORKALA, O. The effect of prolonged treatment with sulphinpyrazone on thromboxane A_2 and prostacyclin in man, 456P
VLASSES, P.H. *see* FERGUSON, R.K., 719
VLASSES, P.H. *see* MOJAVERIAN, P., 809
VON BAHR, C., BIRGERSSON, C., BERTILSSON, L., GÖRANSSON, M., MELLSTRÖM, B., NILSELL, K. & SJÖQVIST, F. Drug metabolism in human liver microsomes: towards marker substrates for different enzymes, 603P
VON BAHR, C., COLLSTE, P., HERMANSSON, J., SVENSSON, L. & TAWARA, K. Dose-dependent relation between propranolol plasma levels and adrenoceptor blockade: role of catecholamine levels, 580P
VON BAHR, C., HERMANSSON, J. & TAWARA, K. Plasma levels of (+) and (−)-propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man, 79
VON BAHR, C. *see* CHIANG, W.T., 590P
VON BAHR, C. *see* TAWARA, K., 580P
VON SASSEN, W. *see* EICHELBAUM, M., 575P
VON WITT, R.J. *see* PETERSON, G.M., 298
de VRIES, J.X. *see* HARENBERG, J., 292
VUOROSALO, D. *see* CHIANG, W.T., 590P

W

WADE, D. *see* FEELY, J., 139P
WADE, D.N. *see* BEGG, E.J., 219
WAHLIN-BOLL, E. *see* MELANDER, A., 579P
WAKEFIELD, V. *see* JACKSON, P.R., 257
WALAN, A. *see* JONSSON, K.-A., 815
WALGER, P. *see* HAVELKA, J., 71S
WALKER, O., ALVAN, G., BEERMANN, B., GUSTAFSSON, L.L., LINDSTRÖM, B.L. & SJÖQVIST, F. The pharmacokinetics of chloroquine in healthy volunteers, 624P
WALLIN, A. & BORÉUS, L.O. Prophylaxis against neonatal hyperbilirubinaemia: the effect of a single dose of phenobarbitone on bilirubin disposition, 605P
WALSH, W.F. & LEE, C.L. Acute and chronic effects of captopril therapy in patients with refractory heart failure, 153S
WALSH, W.F. *see* BARLOW, J., 175S
WALSTAD, R.A., THURMANN-NIELSEN, E., DALE, L.G. & BRUNN, J.N. Blister- and lymphatic fluid studies of ceftazidime, a new cephalosporin with antipseudomonal activity, 626P
WALSTAD, R.A. *see* BERG, K.J., 595P
WALTER, E. *see* HARENBERG, J., 292
WANWIMOLRUK, S. *see* BIRKETT, D.J., 574P
WARRINGTON, S. *see* HASSAN, S., 369
WARRINGTON, S.J. *see* ILIOPOULOU, A., 586P
WATER, J.-M. *see* GROVE, J., 616P
WATSON, I.D., COHEN, H.N., STEWART, M.J., McINTOSH, S.J., SHENKIN, A. & THOMFSON, J.A. Comparative pharmacokinetics of co-trifamole and co-trimoxazole to 'steady state' in normal subjects, 437
WATSON, T.R. *see* DAWSON, M., 453
WEBB, C. *see* BEGG, E.J., 219
WEBER, E. *see* HARENBERG, J., 292
WEBER, E. *see* SCHMIDLIN, O., 799
WEERASURIYA, K. A dose-effect study of S 3341, a new α_2-adrenoceptor agonist, 592P
WEERASURIYA, K., PATEL, L. & HAMER, N.A.J. Comparison of alinidine and propranolol during maximum exercise in normal volunteers, 130P
WEINBERGER, M. *see* BRESLIN, D.J., 139S
WEINBERGER, M. *see* BROWN, J.J., 241S
WEINBERGER, M.H. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension, 127S
WEINSHILBOUM, R. *see* MWALUKO, G., 231
WETTRE, S. *see* KARLBERG, B.E. 133S
WHITE, J.P. *see* MONIE, R.D.H., 110
WHITING, B. *see* DERKX, F.H.M., 139P
WHITING, B. *see* ELLIOTT, H.L., 141P
WHITING, B. *see* ELLIOTT, H.L., 588P
WHITING, B. *see* FOTHERINGHAM, G.H., 595P
WHITING, B. *see* KELMAN, A.W., 247
WHITING, B. *see* KELMAN, A.W., 609P
WHITING, B. *see* STRUTHERS, A.D., 132P
WHITING, B. *see* STRUTHERS, A.D., 843
WIHOLM, B.-E., AGENÄS, I. & BOETHIUS, G. Improving the evaluation of adverse drug reactions by use of drug utilisation and morbidity data, 596P
WIJNANDS, G. *see* HOUBEN, H., 867
WILCOX, R.G. *see* MACDONALD, I.A., 583P
WILD, R.N. *see* MAUDGAL, D.P., 213
WILDEMAN, R.A. *see* KUMANA, C.R., 519
WILDEMAN, R.A. *see* KUMANA, C.R., 529
WILHELMSSON, C. *see* BERGSTRAND, R., 136P
WILKINS, M.R. *see* KENDALL, M.J., 821
WILKINSON, G.R. *see* FEELY, J., 139P
WILKINSON, P.R., TAIT, C., HESP, R. & RAFTERY, E.B. Potassium supplements during long-term thiazide therapy for essential hypertension, 282
WILKINSON, R. *see* FISKEN, R.A., 701
WILLIAMS, I.A. *see* RAE, S.A., 459
WILLIAMS, S.W. *see* FRAME, M.H., 611P
WILLIS, K. *see* KUMANA, C.R., 529
WILSON, J.F. *see* MARSHALL, R.W., 154P
WILSON, K., ORAM, M., HORTH, C.E. & BURNETT, D. The influence of the menstrual cycle on the metabolism of methaqualone in man, 333
WILSON, K. *see* ORAM, M., 341
WILSON, K.C.M. *see* GEORGE, A.J., 146P
WOLFSON, S. *see* BARLOW, J., 175S
WOOD, A.J.J. *see* FEELY, J., 146P
WOOD, A.J.J. *see* FEELY, J., 599P
WOODHOUSE, K.W., HAMILTON, P., LENNARD, A. & RAWLINS, M.D. Melphalan pharmacokinetics in patients with multiple myeloma: an intravenous and oral study, 615P
WOODS, H.F. *see* LENNARD, M.S., 572P
WOODS, H.F. *see* TUCKER, G.T., 743
WOODS, K.L. *see* KENDALL, M.J., 821
WORMSLEY, K.G. *see* BOYD, E.J.S., 15
WORMSLEY, K.G. *see* PEDEN, N.R., 565
WORTHINGTON, D.J. *see* KENDALL, M.J., 821

Y

YAN, K. *see* BLACK, J.L., 464
YLIKORKALA, O. *see* VIINIKKA, L., 456
YOUNG, C.J., DANESHMEND, T.K. & ROBERTS, C.J.C. Pharmacokinetics of ranitidine in hepatic cirrhosis and in the elderly, 152P

YOUNG, J. *see* HARRY, J.D., 584P
YOUNG, M. *see* DODSON, M.E., 141P
YUSUF, S. *see* SLEIGHT, P., 37S

Z

ZANIOL, P. *see* RICCI, S., 209S
ZECH, P.Y. *see* CUISINAUD, G., 489
ZIMMERMAN, R. *see* HARENBERG, J., 292
ZUCCALA, A. *see* STURANI, A., 849
ZUCCHELLI, P. *see* STURANI, A., 849

SUBJECT INDEX

A

Acetylisoniazid, method to prevent loss of isoniazid and, in human plasma, 145P

Acetylsalicylic acid, effect of, on thromboxane A_2 and prostacyclin production and platelet aggregation, 600P

α_1-Acid glycoprotein, increase of, after treatment with amitriptyline, 102

Adenosine, induced bronchoconstriction is not caused by enhanced immunological release of mast cell mediators, 607P

β-Adrenergic blockade, early intravenous β-blockade in myocardial infarction, 37S

β-Adrenergic blocker, β-blockade after myocardial infarction—a statistical view, 15S

—, heart attack trial, 3S

—, hypotension does not explain isoprenaline tachycardia differences between, drugs with and without cardioselectivity, 576P

—, intravenous, during unstable angina and threatened infarction, 29S

—, now you see it, now you don't. Eccentricities and anomalies in the results of β-blocking trials, 51S

—, prophylaxis with, and the community, 45S

—, summary: critical appraisal of present position and practical issues for the future, 63S

—, where are we now, 57S

α_2-Adrenoceptor antagonist, reversal of clonidine induced miosis by, RX 781094, 99

β-Adrenoceptor, comparison of standardized isoprenaline sensitivity tests, 581P

β_2-Adrenoceptor agonist, and thyroid hormones, 447

—, comparison between airways response to a, and histamine in asthmatic and non-asthmatic subjects, 464

—, effect of, on prevalence of peripheral vascular symptoms in hypertensive patients, 833

β-Adrenoceptor blockade, cardiovascular and platelet effects of prostacyclin are unaffected by, in man, 369

—, effect of, on the pressor response to coffee plus smoking, 582P

—, effects of cold exposure on blood pressure, heart rate and forearm blood flow in normotensives during selective and non-selective, 867

—, plasma levels and cardiac electrophysiological effects of melperone in absence and presence of, 591P

—, relationships among timolol doses, plasma concentrations and, 719

β-Adrenoceptor blocker, effect of once-daily, thiazide diuretic combination on the ambulatory blood pressure, 827

—, influence of lipid solubility on sperm immobilizing effect of, 269

β-Adrenoceptor density, lymphocyte, and fitness in athletes, 127P

β-Adrenoceptor response, responsiveness to β-adrenergic receptor stimulation: effects of age are cardioselective, 821

β_2-Adrenoceptor blocker, effects of ICI 118551 on metabolic changes induced by isoprenaline and on tachycardia induced by exercise, 584P

Adverse drug reaction, improving evaluation of, by use of drug utilisation and morbidity data, 596P

Age, bioavailability of labetalol increases with, 304

—, effect of, on responses of human isolated arteries and veins to noradrenaline, 750

—, pharmacokinetics of azapropazone in the elderly, 116

—, responsiveness to β-adrenergic receptor stimulation: effects of, are cardioselective, 821

Agranulocytosis, captopril-induced, associated with an impairment of debrisoquine hydroxylation, 601P

Alcohol, plasma chlorpropamide: a critical factor in chlorpropamide-, flush 579P

Aldosterone, diuretic induced hypokalaemia: relationship to dosage interval and plasma, 449

Aldosterone antagonist, amiloride and spironolactone in fludrocortisone model, 138P

Alimentary motility, methods in human, 757

Alinidine, comparative cardioselective effects of, and propranolol alone and in combination with hydralazine in normal man, 131P

—, comparison of, and propranolol during maximum exercise in normal volunteers, 130P

—, pharmacokinetics of, 148P

Ambulatory monitoring, role of, techniques in a clinical trial of NSAI drug piroxicam, 154P

Amiloride, and spironolactone in fludrocortisone model, 138P

—, effect of a combination of timolol, hydrochlorothiazide and, on 24 hour blood pressure control using ambulatory intra-arterial monitoring, 415

Aminophylline, sustained release, in asthma and its interaction with rimiterol, 110

—, use of, by inhalation, 463

Aminopyrine, interpretation of CO_2 exhalation rate data from demethylation of, and its metabolite monomethylaminoantipyrine, 409

Amiodarone, dose, concentration and effects of, 577P

Amitriptyline, increase of α_1-acid glycoprotein after treatment with, 102

Amoxycillin, biliary excretion of, and ceftriaxone after intravenous administration in man, 213

Ampicillin, azo reduction of sulphasalazine in healthy volunteers, 395

—, effects of, on oral contraceptive steroids in women, 43

Analgesia, minimum effective analgetic blood concentration of pethidine in patients with intractable pain, 385

Analgesic, clinical assessment of, drugs, 754

—, tooth pulp stimulation: a method of determining analgesic efficacy of meptazinol in man, 104

Angiotensin-converting enzyme, long-term efficacy of, inhibition with captopril in mild to moderate essential hypertension, 121S

Angina, intravenous β-blockers during unstable, and threatened infarction, 29S
Angina pectoris, bopindolol in, circulatory effects at rest, during exercise and after nitroglycerin, 131P
—, effect of glyceryltrinitrate ointment on heart rate—corrected systolic time intervals in, 843
Anticholinergic effect, plasma concentration and effect of disopyramide and its mono-dealkylated metabolite administered to healthy subjects, 590P
Antidepressants, placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers, 805
Antihistamines, and visual function: studies of dynamic acuity and the pupillary response to light, 683
— differences in performance impairment due to brompheniramine maleate as a function of the sustained release system, 49
Antihypertensive drugs, sample size for short-term trials of, 265
Antihypertensive efficacy, maintenance of, of captopril despite consistent reduction in daily dosage, 81S
Anti-inflammatory drug, variations in responses to non-steroidal, 691
Antipyrine, assessment of drug metabolism of the liver, 631
—, lack of effect of atenolol in, clearance, 743
Antiarrhythmic agent, evaluation of the cardiac effects following acute and steady state disopyramide, 588P
—, non-invasive evaluation of pharmacokinetic effects of flecainide, a new, 588P
Antisecretory drugs, clinical assessment of, in man, 15
Antitussive agent, double-blind comparison of the respiratory and sedative effects of codeine phosphate and (±)-glaucine phosphate in human volunteers, 555
—, ventilatory and cardiovascular effects of BHT 933 in volunteers, 559
Arachidonic acid, effect of systemic prednisolone on, and prostaglandin E_2 and $F_{2\alpha}$ levels in human cutaneous inflammation, 391
Artery, effect of age on responses of human isolated, and veins to noradrenaline, 750
—, effect of nitroglycerin on peripheral large, in hypertension, 241
Aspirin, effect of acetylsalicylic acid on thromboxane A_2 and prostacyclin production and platelet aggregation, 600P
—, urinary excretion of, 562
Astemizole, antihistamines and visual function: studies of dynamic acuity and the pupillary response to light, 683
Asthma, adenosine-induced bronchoconstriction is not caused by immunological release of mast cell mediators, 607P
—, comparison between airways response to a β-adrenoceptor agonist and histamine in asthmatic and non-asthmatic subjects, 464
—, dose response evaluation of inhaled terbutaline in moderate and acute, wet nebulisation *v* dry aerosol via pear-spacer, 611P
—, effects of M & B 22,948, an orally absorbed mast cell stabiliser, on, induced by exercise and by histamine, 608P
—, sustained-release aminophylline in, and its interaction with rimiterol, 110
—, tiaramide—a new oral drug for the treatment of, 505
—, use of aminophylline by inhalation, 463
Atenolol, antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients, 135P
—, captopril and, combined with hydrochlorothiazide in essential hypertension, 107S
—, comparison of two long-acting preparations of metoprolol with conventional metoprolol and, in healthy men during chronic dosing, 713
—, early intravenous β-blockade in myocardial infarction, 37S
—, effect of β-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients, 833
—, effect of pretreatment with cimetidine on the bioavailability and disposition of, and metoprolol, 67
—, HPLC measurement of, placental transfer and expression in breast milk, 148P
—, in the treatment of essential hypertension during pregnancy, 279
—, lack of effect of, on antipyrine clearance, 743
—, reduces blood pressure and FEV_1 in normal subjects, 445
—, selectivity of the β-adrenoceptor for ventilation in man, 707
Atherosclerotic vascular disease, enzyme-inducers reduce risk of, 606P
Atropine, heart rate and blood pressure responses to intravenous infusions of isoprenaline before and after, 128P
Azapropazone, pharmacokinetics of, in the elderly, 116
Azathioprine, dosage schedule and rejection episodes in renal transplant recipients, 567
Azo reduction, of sulphasalazine in healthy volunteers, 395

B

Bendrofluazide, comparative pharmacological and pharmacokinetic observations on propranolol and, administered separately and concurrently to volunteers, 727
Benorylate, variations in responses to non-steroidal anti-inflammatory drugs, 691
Benzodiazepine, antagonism of the central effects of 3-methylclonazepam, 871
—, do lorazepam-induced deficits in learning result from impaired rehearsal, reduced motivation or increased sedation, 545
Benzodiazepine antagonist, Ro 15-1788 antagonizes the central effects of diazepam without altering diazepam bioavailability, 677
Benzometronidazole, comparison of the pharmacokinetics of metronidazole in man after oral administration of single doses of, and metronidazole, 201
BHT 933, ventilatory and cardiovascular effects of, in volunteers, 559
Bilirubin, prophylaxis against neonatal hyperbilirubinaemia: effect of a single dose of phenobarbitone on, disposition, 605P
Blood cell, catecholamine receptors on, and responsiveness to propranolol in man, 580P
Blood pressure, a study of nadolol to determine its effect on ambulatory, over 24 hours and during exercise, 83
—, atenolol reduces, and FEV_1 in normal subjects, 445

—, control of, and reduction of echo-cardiographically assessed left ventricular mass with once-daily timolol, 89
—, effect of a combination of timolol, hydrochlorothiazide and amiloride on 24 hour, control using ambulatory intra-arterial monitoring, 415
—, effect of once-daily β-adrenoceptor blocker-thiazide diuretic combination on the ambulatory, 827
—, effects of cold exposure on, heart rate and forearm blood flow in normotensives during selective and non-selective β-adrenoceptor blockade, 867
BQ 22708, pharmacokinetics of endralazine in essential hypertensives and normal volunteers, 589P
Bopindolol, in angina pectoris: circulatory effects at rest, during exercise and after nitroglycerin, 131P
Breast milk, disopyramide, and its *N*-monodesalkyl metabolite in, 310
—, HPLC of atenolol: placental transfer and expression in, 148P
—, pyridostigmine in, 565
Brompheniramine maleate, differences in performance impairment due to, as a function of the sustained-release system, 49
Bronchitis, prediction of bronchodilator response to theophylline in chronic, 609P
Bronchodilation, ipratropium bromide and fenoterol by aerosolized solution, 113
Bumetanide, pharmacokinetics and diuretic effect of piretanide and, in chronic renal insufficiency, 595P
Buprenorphine, photographic measurement of miosis in volunteers after i.v., and its relation to other pharmacological effects, 621P
Bupropion, effects of, a new antidepressant drug, and diazepam and their interaction in man, 791
—, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and EEG in healthy volunteers, 153P

C

C 49802B-Ba, differences of sympathomimetic and anticholinergic action of OH-maprotiline and its R(−)-enantiomer, 799
Calcium antagonist, preliminary study of haemodynamic effect of nicardipine in man, 586P
Cancer, morphine metabolism in patients is independent of dose and duration of treatment, 622P
Captopril, acute and chronic effects of, therapy in patients with refractory heart failure, 153S
—, acute and long-term effects of, on exercise cardiac performance and exercise capacity in congestive heart failure, 143S
—, and atenolol combined with hydrochlorothiazide in essential hypertension, 107S
—, beneficial effects of, in left ventricular failure in patients with myocardial infarction, 187S
—, clinical and haemodynamic effects of low dose, in severe chronic heart failure, 161S
—, clinical and haemodynamic responses to, and hydralazine in chronic congestive heart failure: the importance of preload reduction, 217S
—, comparison of acute haemodynamic effects of, and hydralazine in refractory heart failure, 133P
—, comparison of, and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension, 127S
—, experience in hypertension, opening remarks, 69S
—, factors predicting acute and long-term response to, therapy in congestive heart failure, 169S
—, heart rate control in hypertensive patients treated by captopril, 849
—, in congestive heart failure, 193S
—, induced agranulocytosis associated with an impairment of debrisoquine hydroxylation, 601P
—, in essential hypertension, 103S
—, inhibition of prostaglandin synthesis and, 95S
—, in the treatment of mild essential hypertension, 117S
—, long-term efficacy and angiotensin-converting enzyme inhibition with, in mild to moderate essential hypertension, 121S
—, long-term experience of, in the treatment of essential hypertension, 133S
—, long-term experience with, in severe hypertension, 71S
—, long-term, therapy in severe refractory congestive heart failure, 203S
—, long-term, treatment in moderate to severe hypertension, 77S
—, long-term treatment of congestive heart failure with, 223S
—, maintenance of the antihypertensive efficacy of, despite consistent reduction in daily dosage, 81S
—, racial differences in response to low-dose, are abolished by the addition of hydrochlorothiazide, 97S
—, short- and long-term effects of treatment with low dose, in patients with severe congestive heart failure, 231S
—, sustained haemodynamic and clinical effects of, in long-term treatment of severe chronic congestive heart failure, 209S
Carbamazepine, auto- and hetero-induction with, in man, 619P
—, humane monitoring of, 627P
—, microsomal enzyme induction in children: influence of, treatment on antipyrine kinetics, 6β-hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity, 861
Cardiovascular effect, cigarette smoking does not attenuate, of prostacyclin in humans, 97
—, ventilatory and, of BHT 933 in volunteers, 559
Catecholamine receptor, on blood cells and responsiveness to propranolol in man, 580P
Ceftazidime, blister and lymphatic fluid studies of, a new cephalosporin with antipseudomonal activity, 626P
Ceftriaxone, biliary excretion of amoxycillin and, after intravenous administration in man, 213
Central nervous system metabolites, HPLC of monoamine metabolites (MHPG, 5-HIAA and HVA) in CSF and plasma, 617P
Cephalosporin, blister and lymphatic fluid studies of ceftazidime, a new, with antipseudomonal activity, 626P
CGP 12103/A, differences of sympathomimetic and anticholinergic action of OH-maprotiline and its R(−)-enantiomer, 799
Charcoal, effect of activated, on absorption of tolbutamide and valproate in man, 598P
Chlormethiazole, hypnotic response in the elderly—single dose effects of, and dichloralphenazone, 143P

Chlormezanone, a comparison of the effects of, and nitrazepam on sleep, 57
Chlorpromazine, predictive indices for, therapy in schizophrenics, 273
Chlorpropamide, plasma, a critical factor in, alcohol flush, 579
Chloroquine, disposition in man, 624P
—, kinetics of the uptake and elimination of, in children with malaria, 483
—, pharmacokinetics of, in healthy volunteers, 624P
Chlorothiazide, effects of, propranolol and frusemide on erythrocyte cation fluxes in essential hypertension, 593P
Chlorthalidone, captopril in the treatment of essential hypertension, 117S
Cigarette smoking, does not attenuate cardiovascular effects of epoprostenol (prostacyclin) in humans. 97
—, effect of β-adrenoceptor blockade on the pressor response to coffee plus. 582P
Cimetidine, altered disposition and availability of, in liver cirrhotic patients, 421
—, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose, 815
—, does not alter morphine disposition in man, 809
—, does not increase the anticoagulant effect of phenprocoumon, 292
—, -ethanol interaction, 146P
—, effect of intravenous, on the absorbtion of orally administered diazepam and lorazepam, 207
—, effect of, on gonadal function in man, 565
—, influence of, on oral diazepam elimination with measurement of subsequent cognitive change, 739
—, effects of, on serum calcium and parathyroid hormone levels in primary hyperparathyroidism, 701
—, effect of pretreatment with, on bioavailability and disposition of atenolol and metoprolol, 67
—, kinetics in liver cirrhosis, 604P
—, plasma diazepam and lorazepam concentrations following oral administration, with and without, 618P
Cirrhosis, altered disposition and availability of cimetidine in liver, 421
—, cimetidine kinetics in liver, 604P
Clinical trial, β-blockade after myocardial infarction—a statistical view, 15S
—, clinical assessment of antisecretory drugs in man, 15
—, logic and inference in, 171
—, logistics and management of, 25
—, Norwegian propranolol trial in selected patients, 9S
—, now you see it now you don't. Eccentricities and anomalies in the results of β-blocking trials, 51S
—, patient subsets and variation in therapeutic efficacy, 473
—, prophylaxis with β-blockers and the community, 45S
—, role of ambulatory physiological monitoring techniques in a, of NSAI drug piroxicam, 154P
—, sample size for short-term trials of antihypertensive drugs, 265
—, statistical decision theory and, 765
—, the β-blocker heart attack trial, 3S
—, what can we do with the data we throw away, 653
Clonidine, high dose prazosin in the control of rebound hypertension following, withdrawal, 578P
—, reversal of, induces miosis by α_2-adrenoceptor antagonist RX 781094, 99
Clopamide, effect of once daily β-adrenoceptor blocker-thiazide diuretic combination on the ambulatory blood pressure, 827
Clovoxamine, placebo controlled study of the cardiovascular effects of fluvoxamine and, in human volunteers, 805
Coffee, effect of β-adrenoceptor blockade on the pressor response to, plus smoking, 582P
Codeine, added to paracetamol—induced adverse effects but did not increase analgesia, 539
Codeine phosphate, double-blind comparison of the respiratory and sedative effects of, and (±)-glaucine phosphate in human volunteers, 555
Cold exposure, effects of, on blood pressure, heart rate and forearm blood flow in normotensives during selective and non-selective β-adrenoceptor blockade, 867
CO_2 exhalation rate, interpretation of, data from demethylation of aminopyrine and its metabolite monomethylaminoantipyrine, 409
Combination therapy, effect of, with rifampicin and isoniazid on vitamin D metabolism, 144P
Computer analysis, microcomputer technique for collection and analysis of data from skeletal muscle twitches, 154P
Converting enzyme inhibitor, absence of reflex tachycardia during converting enzyme inhibition: evidence against impairment of autonomic reflexes, 129P
—, pharmacodynamics of, cardiovascular, endocrine and autonomic effects of MK 421 (enalapril) and MK 521, 347
Coronary heart disease, effects of nitroglycerin ointment on exercise tolerance, heart rate and blood pressure in patients with, 592P
—, immediate haemodynamic effects of nifedipine during upright exercise in, 585P
—, summary: critical appraisal of present position and practical issues for the future, 63S
Co-trifamole, comparative pharmacokinetics of, and co-trimoxazole to 'steady state' in normal subjects, 437
Co-trimoxazole, comparative pharmacokinetics of co-trifamole and, to 'steady state' in normal subjects, 437
Cystic fibrosis, tubular excretion of β-lactam antibiotics in healthy volunteers and, patients, 611P

D

Data, what can we do with the, we throw away, 653
Debrisoquine, defective metabolism of metoprolol in poor hydroxylators of, 301
—, impaired metabolism of metoprolol in poor hydroxylators of, 572P
Debrisoquine hydroxylation, captopril-induced agranulocytosis associated with an impairment of, 601P
Debrisoquine oxidation, drug metabolism in human liver microsomes: towards marker substrates for different enzymes, 603P
—, evidence for a common defect in the impaired oxidation of substrates in the polymorphism, 602P
—, metabolism of various drugs in subjects with different, and sparteine oxidation phenotypes, 602P
Depression, increase of α_1-acid glycoprotein after treatment with amitriptyline, 102
Dexamphetamine, nomifensine, bupropion and, on performance, subjective feelings, autonomic variables and EEG in healthy volunteers, 153P
Diabetes, plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush, 579P
Diabetes mellitus, once daily *v* twice daily glipizide in, 614P

Diazepam, development of tolerance and cross-tolerance to the actions of, and lorazepam on psychomotor skills in man, 619P
—, effect of intravenous cimetidine on the absorption of orally administered, and lorazepam, 207
—, effect of intravenous, on peak saccadic velocity, 142P
—, effects of bupropion and diazepam and their interaction in man, 791
—, influence of cimetidine on oral, elimination with measurement of subsequent cognitive change, 739
—, plasma, and lorazepam concentrations following oral administration, with and without cimetidine, 618P
—, Ro 15-1788 antagonizes the central effects of, in man without altering, bioavailability, 677
—, serum protein binding of, in maternal and foetal serum during pregnancy, 551
Dichloralphenazone, hypnotic response in the elderly—single dose effects of chlormethiazole and, 143P
Digitalis, short- and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure, 231S
Digitoxin, accumulation, 225
Digoxin, cardiac effect at steady state during combined treatment with quinidine and, 591P
—, effects of, on rubidium-86 uptake by erythrocytes from mothers and babies, 140P
—, justification for routine monitoring of theophylline and, plasma concentrations, 139P
—, metabolism of, and absorption site, 284
—, pharmacodynamic and pharmacokinetic evaluation of interaction between, and disopyramide, 141P
Disopyramide, and its *N*-monodesalkyl metabolite in breast milk, 310
—, evaluation of the cardiac effects following acute and steady state, 588P
—, pharmacodynamic and pharmacokinetic evaluation of interaction between digoxin and, 141P
—, plasma binding of, and mono-*N*-dealkyldisopyramide, 673
—, plasma concentration and effect of, and its mono-dealkylated metabolite administered to healthy subjects, 590P
Disopyramide phosphate, absorption and antidysrhythmic activity of oral, after acute myocardial infarction, 529
—, placebo-controlled study to determine the efficacy of oral, for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction, 519
Doxycycline, pharmacokinetics and plasma steady state levels of, in undernutrition, 785
Drug absorption, an oral preparation to release drugs in the human colon, 405
Drug clearance, food-induced alterations in systemic, 599P
Drug concentration, calculation of, in plasma after equilibrium dialysis, 752
Drug dosage, nalidixic acid kinetics in renal insufficiency, 489
—, OPT: a package of computer programs for parameter optimization in clinical pharmacokinetics, 247
—, sample size for short-term trials of antihypertensive drugs, 265
Drug information, drugline: a new database for evaluated, 597P
Drug interaction, antagonism of the central effects of 3-methylclonazepam, 871
—, between ethanol and nitrazepam and temazepam on human psychomotor performance, 620P
—, cardiac effects at steady state during combined treatment with quinidine and digoxin, 591P
—, cimetidine does not increase the anticoagulant effect of phenprocoumon, 292
—, cimetidine-ethanol interaction, 146P
—, clinical pharmacology of oral contraceptive steroids, 31
—, codeine added to paracetamol—induced adverse effects but did not increase analgesia, 539
—, comparative pharmacokinetics of co-trifamole and co-trimoxazole to steady state in normal subjects, 437
—, comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension, 127S
—, effect of intravenous cimetidine on the absorption of orally administered diazepam and lorazepam, 207
—, effect of pirprofen on glibenclamide kinetics and response, 123
—, effect of pretreatment with cimetidine on bioavailability and disposition of atenolol and metoprolol, 67
—, effects of bupropion and diazepam and their interaction in man, 791
—, enhanced metabolism of mexiletine after phenytoin administration, 219
—, influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change, 739
—, metoprolol pharmacokinetics and the oral contraceptive pill, 120
—, microsomal enzyme induction in children: influence of carbamazepine treatment on antipyrine kinetics, 6β-hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity, 861
—, pharmacodynamic and pharmacokinetic evaluation of interaction between digoxin and disopyramide, 141P
—, pharmacokinetic interaction between theophylline and erythromycin, 495
—, phenytoin: an inhibitor and inducer of primidone metabolism in an epileptic patient, 294
—, sulphinpyrazone can inhibit or induce drug metabolism: effects on tolbutamide and theophylline metabolism in man, 574P
Drugline, a new database for evaluated drug information, 597P
Drug metabolism, assessment of the, capacity of the liver, 631
—, in human liver microsomes: towards marker substrates for different enzymes, 603P
—, various in subjects with different debrisoquine and sparteine oxidation phenotypes, 602P
Drug monitoring, comparative study of saliva and serum paracetamol levels using spectrophotometric method, 107
—, justification for routine monitoring of theophylline and digoxin plasma concentrations, 139P
Drug promotion, and the doctor, 661
—, and the doctor—a reply, 664
Drug release, an oral preparation to release drugs in the human colon, 405
Drug therapy, assessment of, in inflammatory bowel disease, 159
Dysrhythmia, absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction, 529
—, placebo-controlled study to determine the efficacy of disopyramide phosphate for the prophylaxis of ventricular, after acute myocardial infarction, 519

E

ECG response, blood quinidine levels and cardiac effects in white British and Nigerian subjects, 513
Echinococcosis, pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [^{3}H]-mebendazole, 453
Enalapril, comparison of once-a-day and twice-a-day dosage of regimens of, (MK 421) in patients with mild hypertension, 136P
—, pharmacodynamics of converting enzyme inhibition: cardiovascular, endocrine and autonomic effects of, and MK521, 347
Enalapril maleate, and MK521 disposition in man, 357
—, and MK521 in normal volunteers: relationship between plasma drug levels and the renin angiotensin system, 363
β-Endorphin, β-lipotrophin immunoreactivity correlates with maternal prolactin in first post-partum week, 146P
Endralazine, pharmacokinetics of, (BQ22708) in essential hypertensives and normal volunteers, 589P
Enzyme induction, microsomal, in children: influence of carbamazepine treatment on antipyrine kinetics, 6β-hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity, 861
—, time course of liver microsomal, in man, 571P
Epilepsy, auto- and hetero-induction with carbamazepine in man, 619P
—, effect of seizure control of adjusting plasma phenytoin within the therapeutic range, 627P
—, enzyme induction in children: influence of carbamazepine treatment in antipyrine kinetics, 6β-hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity, 861
—, intra-dose variation in plasma protein binding of sodium valproate in, 399
—, phenytoin: an inhibitor and inducer of primidone metabolism in an epileptic patient, 294
—, plasma protein binding of phenytoin in 100 epileptic patients, 298
Epoprostenol, see **prostacyclin**
Erythromycin, pharmacokinetic interaction between theophylline and, 495
Ethanol, cimetidine, interaction, 146P
—, interactions between, and nitrazepam and temazepam on human psychomotor performance, 620P
Ethylenediamine, comparative disposition of theophylline and, given as aminophylline to human volunteers, 610P
Equilibrium dialysis, calculation of drug concentration in plasma after, 752
Excretion, urinary, of aspirin, 562
Exercise, acute effects of metoprolol or propranolol on metabolic and cardiorespiratory responses to, in hypertensive patients, 583P
—, a study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during, testing, 83
—, comparison of alinidine and propranolol during maximum, in normal volunteers, 130P
—, effects of ICI 118551 on metabolic changes induced by isoprenaline and on tachycardia induced by, 584P
—, effects of nitroglycerin ointment on, tolerance, heart rate and blood pressure in patients with coronary heart disease, 592P
—, immediate haemodynamic effects of nifedipine during upright, in coronary heart disease, 585P

F

Fenfluramine, effects of, on *in vitro* platelet aggregation, 466
Fenoprofen, variations in responses to non-steroidal anti-inflammatory drugs, 691
Fenoterol, ipratropium bromide and, by aerosolized solution, 113
First pass metabolism, influence of food on oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol, 73
Fitness, lymphocyte β-adrenoceptor density and, in athletes, 127P
Flecainide, effect of, on human sperm motility, 147P
—, non-invasive evaluation of pharmacodynamic effects of, a new antiarrhythmic agent, 588P
Fluvoxamine, placebo-controlled study of the cardiovascular effects of, and clovoxamine in human volunteers, 805
Food, induced alteration in systemic clearance of drugs, 599P
—, influence of, on oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol, 73
Forced expiratory volume, atenolol reduces blood pressure and, in normal subjects, 445
Frusemide, controlled trial of, *v* high-dose thiazide in resistant hypertension, 137P
—, effects of chlorothiazide, propranolol and, on erythrocyte cation fluxes in essential hypertension, 593P
—, *in vitro* studies of the hydrolysis of, in gastrointestinal juices, 306

G

GABA, is measurement of free, concentrations in human CSF the most appropriate index of brain GABA activity, 616P
Gastric antacid, absorption of mexiletine after treatment with gastric antacids, 746
Gastric juice, *in vitro* studies of the hydrolysis of frusemide in gastrointestinal juices, 306
Gastric secretion, effect of labetalol on, and gastrin secretion in man, 744
—, ranitidine upon meal-induced: oral pharmacokinetics and plasma concentration effect relationships, 187
Gastrointestinal disease, nutritional support of patients with, 315
Gastrointestinal tract, methods in human alimentary motility, 757
Genetic defect, defective metabolism of metoprolol in poor hydroxylators of debrisoquine, 301
Glaucine phosphate, double-blind comparison of the respiratory and sedative effects of codeine phosphate and, in human volunteers, 555
Glibenclamide kinetics, effect of pirprofen on, and response, 123
Glipizide, once daily *v* twice daily, in diabetes mellitus, 614P
Glyceryl trinitrate, effect of, ointment on heart rate—corrected systolic time interval in angina pectoris, 843
—, pharmacokinetic studies of various preparations of, 779

—, systolic time intervals in myocardial ischaemia: effect of, ointment, 132P
Gonadal function, effect of cimetidine on, in man, 565

H

Heart attack, the β-blocker, trial, 3S
Heart failure, captopril, experience in, opening remarks, 141S
—, chronic, clinical and haemodynamic effects of low dose captopril in severe, 161S
—, comparison of acute haemodynamic effects of captopril and hydralazine in refractory, 133P
—, congestive, acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in, 143S
—, congestive, captopril in, 193S
—, congestive, clinical and haemodynamic responses to captopril and hydralazine in chronic, the importance of preload-reduction, 217S
—, congestive, factors predicting acute and long-term response to captopril therapy in, 169S
—, congestive, long-term captopril therapy in severe refractory, 203S
—, congestive, long-term treatment of, with captopril, 223S
—, congestive, regional circulatory response to converting enzyme inhibition in, 179S
—, congestive, short- and long-term effects of treatment with low dose captopril in patients with severe, 231S
—, congestive, sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic, 209S
—, refractory, acute and chronic effects of captopril therapy in patients with, 153S
Heart rate, and blood pressure responses to intravenous infusions of isoprenaline before and after atropine, 128P
—, control in hypertensive patients treated by captopril, 849
—, effect of glyceryl trinitrate ointment on, —corrected systolic time intervals in angina pectoris, 843
Hepatic cirrhosis, pharmacokinetics of ranitidine in, and in the elderly, 152P
Hepatosplenic schistosomiasis, effect of, on pharmacokinetics of metronidazole and labetalol, 152P
Hepatotoxicity, isoniazid, in relation to acetylator phenotype and isoniazid metabolism, 575P
Histamine, comparison between airways response to a β-adrenoceptor agonist and, in asthmatic and non-asthmatic subjects, 464
Homatropine, pharmacological method for measuring penetration of topical mydriatic drugs in man, 468
Hydralazine, acetylator status and hypotensive response to, 134P
—, clinical and haemodynamic responses to captopril and, in chronic congestive heart failure: the importance of preload reduction, 217S
—, comparative cardiovascular effects of alinidine and propranolol alone and in combination with, in normal man, 131P
—, comparison of acute haemodynamic effects of captopril and, in refractory heart failure, 133P
—, once daily in hypertension, 133P
—, pyruvate in fast and slow acetylators, 150P
Hydrochlorothiazide, captopril and atenolol combined with, in essential hypertension, 107S
—, captopril in essential hypertension, 103S
—, comparison of captopril and, alone and in combination in mild to moderate essential hypertension, 127S
—, diuretic induced hypokalaemia: relationship to dosage interval and plasma aldosterone, 449
—, effect of a combination of timolol, and amiloride on 24 hour blood pressure control using ambulatory intra-arterial monitoring, 415
—, long-term experience of captopril in the treatment of essential hypertension, 133S
—, racial differences in response to low-dose captopril are abolished by the addition of, 97S
Hyperbilirubinaemia, prophylaxis against neonatal, effect of a single dose of phenobarbitone on bilirubin disposition, 605P
Hyperparathyroidism, effects of cimetidine on serum calcium and parathyroid hormone levels in primary, 701
Hypertension, acetylator status and hypotensive response to hydralazine, 134P
—, acute and chronic effects of oxprenolol and propranolol on peripheral blood flow in hypertensive patients, 733
—, acute effects of metoprolol or propranolol on metabolic and cardiorespiratory responses to exercise in hypertensive patients, 583P
—, antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients, 135P
—, atenolol in the treatment of essential, during pregnancy, 279
—, captopril and atenolol combined with hydrochlorothiazide in essential, 107S
—, captopril, experience in, opening remarks, 69S
—, captopril in essential, 103S
—, captopril in the treatment of mild essential, 117S
—, comparative pharmacological and pharmacokinetic observations on propranolol and bendrofluazide administered separately and concurrently to volunteers, 727
—, comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension, 127S
—, comparison of once-a-day and twice-a-day dosage regimens of enalapril (MK 421) in patients with mild, 136P
—, comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing, 713
—, concentration effect modelling of trimazosin and its major metabolites, 135P
—, control of blood pressure and reduction of echo-cardiographically assessed left ventricular mass with once-daily timolol, 89
—, controlled trial of frusemide *v* high-dose thiazide in resistant, 137P
—, effect of β-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in, 833
—, effect of nitroglycerin on peripheral large arteries in, 241
—, effect of propranolol on luteinising hormone and prolactin plasma concentrations in hypertensive women, 839

—, effects of chlorothiazide, propranolol and frusemide on erythrocyte cation fluxes and essential, 593P
—, heart rate control in hypertensive patients treated by captopril, 849
—, high dose prazosin in the control of rebound, following clonidine withdrawal, 578P
—, hydralazine once daily in, 133P
—, long-term captopril treatment in moderate to severe, 77S
—, long-term efficacy of angiotensin converting enzyme inhibition with captopril in mild to moderate essential, 121S
—, long-term experience of captopril in the treatment of essential, 133S
—, long-term experience with captopril in severe, 71S
—, pharmacokinetics of endralazine in essential, and normal volunteers, 589P
Hyperventilation, selectivity of the β-adrenoceptor for ventilation in man, 707
Hypnotic, response in the elderly—single dose effects of chlormethiazole and dichloralphenazone, 143P
Hypokalaemia, diuretic induced, relationship to dosage intervals and plasma aldosterone, 449
—, K sparing potency of prorenoate K relative to spironolactone, 594P
—, relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced, 257
—, time courses of urine electrolyte and plasma potassium responses to treatment with metolazone and spironolactone, 149P
Hypotension, reduces liver blood flow and clearance of lignocaine in man, 139P

I

Ibuprofen, variations in responses to non-steroidal anti-inflammatory drugs, 691
ICI 118551, effects of, on metabolic changes induced by isoprenaline and on tachycardia induced by exercise, 584P
Indomethacin, alteration of plasma prednisolone levels by, and naproxen, 459
—, clinical and pharmacokinetic study of, in standard and slow release formulations, 286, 612P
—, variations in responses to non-steroidal anti-inflammatory drugs, 691
Inflammatory bowel disease, assessment of drug therapy in, 159
Insulin, and glucose responses to salbutamol after carbohydrate loading, 614P
Ipratropium bromide, and fenoterol by aerosolized solution, 113
Isoniazid, effect of combination therapy with rifampicin and, on vitamin D metabolism, 144P
—, hepatotoxicity in relation of acetylator phenotype and, metabolism, 575P
—, method to prevent loss of, and acetylisoniazid in human plasma, 145P
Isoprenaline, comparison of standardized, sensitivity tests, 581P
—, effects of ICI 118551 on metabolic changes induced by, and tachycardia induced by exercise, 584P
—, heart rate and blood pressure responses to intravenous infusions of isoprenaline before and after atropine, 128P
—, hypotension does not explain, tachycardia differences between β-adrenoceptor blocking drugs with and without cardioselectivity, 576P

K

Ketamine, pharmacokinetics of, in children, 144P

L

Labetalol, bioavailability of, increases with age, 304
—, effect of hepatosplenic schistosomiasis on pharmacokinetics of metronidazole and, 152P
—, effect of β-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients, 833
—, effect of, on gastric acid and gastrin secretion in man, 744
—, influence of food on oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol, 73
—, method for monitoring drug effects on male sexual response: effects of single dose, 695
Labour, routes of meptazinol conjugation in the neonate, 748
Learning, do lorazepam-induced deficits in, result from impaired rehearsal, reduced motivation, or increased sedation, 545
Left ventricle, control of blood pressure and reduction of echo-cardiographically assessed, mass with once daily timolol, 89
Left ventricular failure, beneficial effects of captopril in, in patients with myocardial infarction, 187S
Lignocaine, dosage schedules for transition from intravenous, to oral tocainide following acute myocardial infarction, 586P
—, hypotension reduces liver blood flow and clearance of, in man, 139P
Lipid solubility, influence of, on sperm immobilizing effect of β-adrenoceptor blocking drugs, 269
Lipoprotein level, enzyme-inducers reduce the risk of atherosclerotic vascular disease, 606P
β-Lipotrophin, maternal β-endorphin/, immunoreactivity correlates with maternal prolactin in first post-partum week, 146P
Liver, assessment of the drug metabolism capacity of, 631
Liver blood flow, hypotension reduces, and clearance of lignocaine in man, 139P
—, prostacyclin increases apparent, 572P
Lorazepam, development of tolerance and cross-tolerance to the actions of diazepam and, on psychomotor skills in man, 619P
—, do, induced deficits in learning result from impaired rehearsal, reduced motivation or increased sedation, 545

—, effect of intravenous cimetidine on the absorption of orally administered diazepam and, 207
—, fluctuations in plasma, levels during first 6 h after oral administration, 141P
—, plasma diazepam and, concentrations following oral administration, with and without cimetidine, 618P
Luteinising hormone, effect of propranolol in, and prolactin concentrations in hypertensive women, 839

M

M&B 22,948, effects of, an orally absorbed mast cell stabiliser, on asthma induced by exercise and by histamine, 608P
Malaria, kinetics of uptake and elimination of chloroquine in children with, 483
Maprotiline, differences of sympathomimetic and anticholinergic action of OH-, and its R(−)-enantiomer, 799
Mebendazole, pharmacokinetics and bioavailability of, in man: a pilot study using [^{3}H]-mebendazole, 453
Melperone, plasma levels and cardiac electrophysiological effects of, in absence and presence of β-adrenoceptor blockade, 591P
Melphalan, pharmacokinetics in patients with multiple myeloma: an intravenous and oral study, 615P
Menstrual cycle, influence of, on the metabolism and clearance of methaqualone, 333
Meptazinol, routes of, conjugation in the neonate, 748
—, tooth pulp stimulation: a method of determining analgesic efficacy of, in man, 104
Methaqualone, influence of menstrual cycle on the metabolism and clearance of, 333
—, influence of oral contraceptives on metabolism of, in man, 341P
3-Methylclonazepam, antagonism of the central effects of, 871
α-Methyldopa, α-methyldopamine and α-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase, 231
α-Methyldopamine, α-methyldopa, and α-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase, 231
α-Methylnoradrenaline, α-methyldopa, and α-methyldopamine; substrates for the thermolabile form of human platelet phenol sulphotransferase, 231
Metronidazole, effect of hepatosplenic schistosomiasis on pharmacokinetics of, and labetalol, 152P
Metolazone, time courses of urine electrolyte and plasma potassium responses to treatment with, and spironolactone, 149P
Metoprolol, acute effects of, or propranolol on metabolite and cardiorespiratory responses to exercise in hypertensive patients, 583P
—, comparison of two long-acting preparations of, with conventional, and atenolol in healthy men during chronic dosing, 713
—, defective metabolism of, in poor hydroxylators of debrisoquine, 301
—, effect of pretreatment with cimetidine on bioavailability and disposition of atenolol and, 67
—, impaired metabolism of, in poor hydroxylators of debrisoquine, 572P
—, pharmacokinetics and the oral contraceptive pill, 120
—, selectivity of the β-adrenoceptor for ventilation in man, 707
Metronidazole, comparison of the pharmacokinetics of, in man after oral administration of single doses of benzoylmetronidazole and, 201
Mexiletine, absorption of, after treatment with gastric antacids, 746
—, enhanced metabolism of, after phenytoin administration, 219
—, pharmacokinetics of, in renal insufficiency, 431
Miosis, photographic measurement of, in volunteers after i.v. buprenorphine and its relation to other pharmacological effects, 621P
—, reversal of clonidine induced, by α_2-adrenoceptor antagonist RX 781094, 99
MK421, pharmacodynamics of converting enzyme inhibition: cardiovascular, endocrine and autonomic effects of, and MK521, 347
MK521, enalapril maleate and, disposition in man, 357
—, enalapril maleate and, in normal volunteers: relationship between plasma drug levels and the renin angiotensin system, 363
—, pharmacodynamics of converting enzyme inhibition: cardiovascular, endocrine and autonomic effects of MK421 and, 347
Monoethylxanthine, levels of, in sera of theophylline treated patients, 608P
Mono-*N*-dealkyldisopyramide, plasma binding of disopyramide and, 673
Morphine, cimetidine does not alter, disposition in man, 809
—, disposition of, in cerebrospinal fluid after epidural administration, 622P
Morphine metabolism, in cancer patients is independent of dose and duration of treatment, 622P
—, inter and intraindividual comparison of, *in vitro* and *in vivo* in man, 573P
Multiple myeloma, melphalan pharmacokinetics in patients with, an intravenous and oral study, 615P
Mydriatic administration, pharmacological method for measuring penetration of topical mydriatic drugs in man, 468
Myocardial infarction, absorption and antidysrhythmic activity of oral disopyramide phosphate after acute, 529
—, β-blockade after myocardial infarction—a statistical view, 15S
—, beneficial effects of captopril in left ventricular failure in patients with, 187S
—, dosage schedules for transition from intravenous lignocaine to oral tocainide following acute, 586P
—, early intravenous β-blockade in, 37S
—, metabolism of sulphinpyrazone and interactions occurring within the gastrointestinal tract, 599P
—, placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute, 519
—, prophylaxis with β-blockers and the community, 45S
—, where are we now, 57S
Myocardial ischaemia, intravenous β-blockers during unstable angina and threatened infarction, 29S

N

Nadolol, antihypertensive and renal haemodynamic effects of atenolol and, in elderly hypertensive patients, 135P
—, a study of, to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing, 83
Nalidixic acid, kinetics in renal insufficiency, 489
Naproxen, alteration of plasma prednisolone levels by indomethacin and, 459
Nicardipine, preliminary study of haemodynamic effects of, a new calcium antagonist, in man, 586P
Nifedipine, immediate haemodynamic effects of, during upright exercise in coronary heart disease, 585P
Nitrazepam, a comparison of the effects of chlormezanone and, on sleep, 57
—, interactions between ethanol and, and temazepam on human psychomotor performance, 620P
Nitroglycerin, bopindolol in angina pectoris: circulatory effects at rest, during exercise and after, 131P
—, effect of, on peripheral large arteries in hypertension, 241
—, effects of, ointment on exercise tolerance, heart rate and blood pressure in patients with coronary heart disease, 592P
Nomenclature, symbols in pharmacokinetics, 7
Nomifensine, bupropion, and dexamphetamine on performance, subjective feelings, autonomic variables and EEG in healthy volunteers, 153P
—, determination of, in human plasma by HPLC, 617P
Noradrenaline, effect of age on responses of human isolated arteries and veins to, 750
Nutrition, pharmacokinetics and plasma steady state levels of doxycycline in undernutrition, 785
—, support of patients with gastrointestinal disease, 315

O

OPT, a package of computer programs for parameter optimisation in clinical pharmacokinetics, 247
—, evaluation of kinetic parameter estimation from routine clinical pharmacokinetic data, 595P
Oral contraceptive, clinical pharmacology of, steroids, 31
—, effects of ampicillin on, steroids in women, 43
—, influence of, on metabolism of methaqualone on man, 341
—, metoprolol pharmacokinetics and the, pill, 120
Osazolo-azepine, ventilatory and cardiovascular effects of BHT 933 in volunteers, 559
Otitis media, what makes GPs prescribe antibiotics for, 151P
Oxmetidine, cimetidine but not, penetrates into the cerebrospinal fluid after single intravenous dose, 815
Oxprenolol, acute and chronic effect of, and propranolol on peripheral blood flow in hypertensive patients, 733
—, effect of β-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients, 833

P

Paracetamol, codeine added to, induced adverse effects but did not increase analgesia, 539
—, comparative study of saliva and serum, levels using spectrophotometric method, 107
Parathyroid hormone, effects of cimetidine on serum calcium and, levels in primary hyperparathyroidism, 701
Penicillin, tubular excretion of β-lactam antibiotics in healthy volunteers and in cystic fibrosis patients, 611P
Perhexiline, single dose, pharmacokinetics in human volunteers, 623P
Peripheral blood flow, acute and chronic effect of oxprenolol and propranolol on, in hypertensive patients, 733
Pethidine, minimum effective analgetic blood concentration of, in patients with intractable pain, 385
Pharmacokinetics, symbols in, 7
Phenacetin, kinetics and metabolism of, in, abusers, 613P
Phenobarbitone, prophylaxis against neonatal hyperbilirubinaemia: effect of a single dose of, on bilirubin disposition, 605P
Phenol sulphotransferase, α-methyldopa, α-methyldopamine, and α-methylnoradrenaline: substrates for the thermolabile form of human platelet, 231
Phenprocoumon, cimetidine does not increase the anticoagulant effect of, 292
Phenytoin, an inhibitor and inducer of primidone metabolism in an epileptic patient, 294
—, effect of seizure control of adjusting plasma, within the therapeutic range, 627P
—, enhanced metabolism of mexiletine after, administration, 219
—, plasma protein binding of, in 100 epileptic patients, 298
Pindolol, effect of once daily β-adrenoceptor blocker-thiazide diuretic combination on the ambulatory blood pressure, 827
Piretanide, oral, in chronic renal failure, 857
—, pharmacokinetics and diuretic effect of, and bumetanide in chronic renal insufficiency, 595P
Piroxicam, role of ambulatory physiological monitoring techniques in clinical trial of, 154P
Pirprofen, effect of, on glibenclamide kinetics and response, 123
Placental transfer, HPLC on atenolol:, and expression in breast milk, 148P
Platelet aggregation, effect of acetylsalicylic acid on thromboxane A_2 and prostacyclin production and, 600P
—, effects of fenfluramine on *in vitro*, 466
Potassium, time courses of urine electrolyte and plasma potassium responses to treatment with metolazone and spironolactone, 149P
Potassium chloride, relative potency of spironolactone, triamterene and, in thiazide-induced hypokalaemia, 257
Potassium concentration, diuretic induced hypokalaemia: relationship to dosage interval and plasma aldosterone, 449
Prazosin, high dose, in control of rebound hypertension following clonidine withdrawal, 578P
Prednisolone, alteration of plasma, levels by indomethacin and naproxen, 459
—, binding of, in human serum and to recrystallized human albumin *in vitro*, 667

—, effect of systemic, on arachidonic acid, and prostaglandin E_2 and $F_{2\alpha}$ levels in human cutaneous inflammation, 391
Pregnancy, atenolol in the treatment of essential hypertension during, 279
—, serum protein binding of diazepam in maternal and foetal serum during, 551
Pressor response curve, analysis of pressor dose-response curves in human subjects, 128P
Primidone, phenytoin: an inhibitor and inducer of, metabolism in an epileptic patient, 294
Prolactin, effect of propranolol in luteinising hormone and, plasma concentrations in hypertensive women, 839
—, maternal β-endorphin/β-lipotrophin immunoreactivity correlates with maternal, in first post-partum week, 146P
Prophylactic, tiaramide—a new oral drug for the treatment of asthma, 505
Propranolol, acute and chronic effects of oxprenolol and, on peripheral blood flow in hypertensive patients, 733
—, acute effects of metoprolol or, on metabolic and cardiorespiratory responses to exercise in hypertensive patients, 583P
—, catecholamine receptors on blood cells and responsiveness to, in man, 580P
—, comparative cardiovascular effects of alinidine and, alone and in combination with hydralazine in normal man, 131P
—, comparative pharmacological and pharmacokinetic observations on, and bendrofluazide administered separately and concurrently to volunteers, 727
—, comparison of alinidine and, during maximum exercise in normal volunteers, 130P
—, drug metabolism in human liver microsomes: towards marker substrates for different enzymes, 603P
—, effect of β-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients, 833
—, effect of, on luteinising hormone and prolactin plasma concentrations in hypertensive women, 839
—, effects of chlorothiazide, and frusemide on erythrocyte cation fluxes in essential hypertension, 593P
—, Norwegian, trial in selected patients, 9S
—, plasma levels of (+) and (−)-propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man, 79
—, racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide, 97S
—, selectivity of the β-adrenoceptor for ventilation in man, 707
Prorenoate K, K sparing potency of, relative to spironolactone, 594P
Prostacyclin, cardiovascular and platelet effects of, are unaffected by β-adrenoceptor blockade in man, 369
—, cigarette smoking does not attenuate cardiovascular effects of, in humans, 97
—, effect of acetylsalicylic acid on thromboxane A_2 and, production and platelet aggregation, 600P
—, effect of prolonged treatment with sulphinpyrazone on thromboxane A_2 and, in man, 456
—, increases apparent liver blood flow, 572P
—, inhibition of vascular, production by plasma from healthy subjects and patients with severe renal impairment, 379
—, side effects occurring during administration of, in man, 177
Prostaglandin, effect of systemic prednisolone on arachidonic acid and, E_2 and $F_{2\alpha}$ levels in human cutaneous inflammation, 391
—, inhibition of, synthesis and captopril, 95S
Protein binding, intra-dose variation in plasma, of sodium valproate in epileptic patients, 399
—, plasma binding of disopyramide and mono-*N*-dealkylpyramide, 673
—, relative importance of albumin, lipoproteins and orosmucoid for serum binding variations of basic, neutral and acidic drugs, 574P
—, serum, of diazepam in maternal and foetal serum during pregnancy, 551
Proxyphylline, elimination of, and its metabolites, 608P
Psychomotor function, differences in performance impairment due to brompheniramine maleate as a function of the sustained-release system, 49
Pyridostigmine, in human breast milk, 565

Q

Quinidine, blood, levels and cardiac effects on white British and Nigerian subjects, 513
—, cardiac effects at steady state during combined treatment with, and digoxin, 591P

R

Race, blood quinidine levels and cardiac effects in white British and Nigerian subjects, 513
—, differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide, 97S
Ranitidine, pharmacokinetics of, in hepatic cirrhosis and in the elderly, 152P
—, single dose pharmacokinetics and absolute bioavailability in man, 195
—, upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships, 187
Renal failure, oral piretanide in chronic, 857
Renal impairment, inhibition of vascular prostacyclin production *in vitro* by plasma from healthy subjects and patients with severe, 379
Renal insufficiency, nalidixic acid kinetics in, 489
—, pharmacokinetics and diuretic effect of piretanide and bumetanide in chronic, 595P
—, pharmacokinetics of mexiletine in, 431
Renal transplant, azathioprine dosage schedule and rejection episodes in, recipients, 567
Renin angiotensin system, enalapril maleate and MK521 in normal volunteers: relationship between plasma drug levels and, 363
Rifampicin, clinical pharmacology of oral contraceptive steroids, 31
—, effect of combination therapy with, and isoniazid on vitamin D metabolism, 144P
Rimiterol, sustained release aminophylline in asthma and its interaction with, 110

Ro 15-1788, antagonism of the central effects of 3-methylclonazepam, 871
—, antagonizes the central effects of diazepam in man without altering diazepam bioavailability, 677
Rubidium uptake, effects of digoxin on, by erythrocytes from mothers and babies, 140P

S

Saccadic eye movement, effect of intravenous diazepam on peak saccadic velocity, 142P
Salbutamol, insulin and glucose responses to, after carbohydrate loading, 614P
Saliva, comparative study of, and serum paracetamol levels using spectrophotometric method, 107
Schizophrenia, predictive indices for chlorpromazine therapy on schizophrenics, 273
Serum albumin, binding of prednisolone in human serum and to recrystallized human, *in vitro*, 667
Serum calcium, effects of cimetidine on, and parathyroid hormone levels in primary hyperparathyroidism, 701
Sexual response, method for monitoring drug effects on male, effect of single dose labetalol, 695
Side effect, method for monitoring drug effects on male sexual response: effect of single dose labetalol, 695
—, occurring during administration of prostacyclin in man, 177
Sleep, a comparison of the effects of chlormezanone and nitrazepam on, 57
Sodium valproate, intra-dose variation in plasma protein binding of, in epileptic patients, 399
Sparteine oxidation, drug metabolism in human liver microsomes: towards marker substrates for different enzymes, 603P
—, metabolism of various drugs in subjects with different debrisoquine and, oxidation phenotypes, 602P
Sperm motility, effect of flecainide on human, 147P
—, influence of lipid solubility on sperm immobilizing effect of β-adrenoceptor blocking drugs, 269
Spironolactone, amiloride and, in fludrocortisone model, 138P
—, K sparing potency of prorenoate K relative to, 594P
—, relative potency of, triamterene and potassium chloride in thiazide-induced hypokalaemia, 257
—, time courses of urine electrolyte and plasma potassium responses to treatment with metolazone and, 149P
Statistical analysis, patient subsets and variation in therapeutic efficacy, 473
Statistical decision theory, and clinical trials, 765
Statistical significance test, 325
Subsets analysis, patient subsets and variation in therapeutic efficacy, 473
Suicide attempt, survey of acute intoxication cases during 1979–1982 in Oulu, 597P
Sulphapyridine, an oral preparation to release drugs in the human colon, 405
Sulphasalazine, azo reduction of, in healthy volunteers, 395
Sulphinpyrazone, can inhibit or induce drug metabolism: effect on tolbutamide and theophylline metabolism in man, 574P
—, effect of prolonged treatment with, on thromboxane A_2 and prostacyclin in man, 456
—, metabolism of, and interactions occurring within the gastrointestinal tract, 599P
Sulphonamide, comparative pharmacokinetics of co-trifamole and co-trimoxazole to steady state in normal subjects, 437
Symbols, in pharmacokinetics, 7
Systolic time interval, in myocardial ischaemia: effect of glyceryl trinitrate ointment, 132P

T

Temazepam, interaction between ethanol and nitrazepam and, on human psychomotor performance, 620P
Terbutaline, β_2-adrenoceptor agonists and thyroid hormones, 447
—, dose response evaluation of inhaled, in moderate and acute asthma: wet nebulisation *v* dry aerosol via pear-spacer, 611P
—, responsiveness to β-adrenergic receptor stimulation: effects of age are cardioselective, 821
Terfenadine, antihistamines and visual function: studies on dynamic acuity and the pupillary response to light, 683
The Third S.K. & F. Prize Lecture, the clinical pharmacology of oral contraceptive steroids, 31
Theophylline, comparative disposition of, and ethylenediamine given as aminophylline to human volunteers, 610P
—, justification for routine monitoring of, and digoxin plasma concentrations, 139P
—, levels of monomethylxanthines in sera of, treated patients, 608P
—, pharmacokinetic interaction between, and erythromycin, 495
—, prediction of bronchodilator response to, in chronic bronchitis, 609P
—, pharmacokinetics of, a dose-range study, 769
—, treatment of children with a single dose a day of sustained release, 290
Theophylline metabolism, sulphinpyrazone can inhibit or induce drug metabolism: effects on tolbutamide and, in man, 574P
Thiazide, controlled trial of frusemide *v* high-dose, in resistant hypertension, 137P
Thromboxane A_2, effect of acetylsalicylic acid on, and prostacyclin production and platelet aggregation, 600P
—, effect of prolonged treatment with sulphinpyrazone on, and prostacyclin in man, 456
Thyroid hormone, β_2-adrenoceptor agonists and, 447
Tiaramide, a new oral drug for the treatment of asthma, 505
Timolol, control of blood pressure and reduction of echocardiographically assessed left ventricular mass with once-daily, 89
—, effect of a combination of, hydrochlorothiazide and amiloride on 24 hour blood pressure control using ambulatory intra-arterial monitoring, 415
—, relationships among, doses plasma concentrations and β-adrenoceptor blocking activity, 719
Tocainide, dosage schedules for transition from intravenous lignocaine to oral, following acute myocardial infarction, 586P
Tolbutamide, effect of activated charcoal on absorption of, and valproate in man, 598P

Tolbutamide metabolism, sulphinpyrazone can inhibit or induce drug metabolism: effects of and theophylline metabolism in man, 574P
Transcortin, binding of prednisolone in human serum and to recrystallized human albumin *in vitro*, 667
Triamterene, relative potency of spironolactone, and potassium chloride in thiazide-induced hypokalaemia, 257
Trimazosin, concentration effect modelling of, and its major metabolite, 135P
Trimethoprim, comparative pharmacokinetics of co-trifamole and co-trimoxazole to steady state in normal subjects, 437
Triprolidine, antihistamines and visual function, studies on dynamic acuity and the pupillary response to light, 683
Tropicamide, pharmacological method for measuring penetration of topical mydriatic drugs in man, 468

U

Urinary tract infection, comparative pharmacokinetics of co-trifamole and co-trimoxazole to steady state in normal subjects, 437

V

Valproate, effect of activated charcoal on absorption of tolbutamide and, in man, 598P
Ventilation, and cardiovascular effects of BHT 933 in volunteers, 559
Verapamil, administration by inhalation: study to assess the possibility of self administration, 587P
—, pharmacokinetics and effects of, in patients, 578P
Visual function, antihistamines and, studies on dynamic acuity and the visual response to light, 683
Vitamin D, effect of combination therapy with rifampicin and isoniazid on, metabolism, 144P

British Journal of Clinical Pharmacology

VOLUME 14 SUPPLEMENT 1 1982

page

3S FURBERG, C. The β-blocker heart attack trial.

7S Discussion.

9S HANSTEEN, VIGGO. The Norwegian propranolol trial in selected patients.

13S Discussion.

15S LEWIS, J.A. β-blockade after myocardial infarction–a statistical view.

23S Discussion.

25S Panel Discussion.

29S NORRIS, R.M., BARNABY, P.F. & GEARY, G.G. Intravenous β-blockers during unstable angina and threatened infarction.

35S Discussion.

37S SLEIGHT, P., YUSUF, S., RAMSDALE, D., ROSSI, P., PETO, R., BENNETT, D., BRAY, C. & FURSE, L. Early intravenous β-blockade in myocardial infarction.

41S Panel Discussion.

45S ROSE, G. Prophylaxis with β-blockers and the community.

49S Discussion.

51S HAMPTON, J.R. Now you see it, now you don't. Eccentricities and anomalies in the results of β-blocking trials.

57S JULIAN, D.G. Where are we now?

59S Panel Discussion.

63S CHAMBERLAIN, D.A. Summary: critical appraisal of present position and practical issues for the future.

VOLUME 14 SUPPLEMENT 2 1982

69S TARAZI, R.C. Captopril experience in hypertension—opening remarks.

71S HAVELKA, J., BOERLIN, H.J., STUDER, A., GREMINGER, P., TENSCHERT, W., LUESCHER, T., SIEGENTHALER, W., VETTER, W., WALGER, P. & VETTER, H. Long-term experience with captopril in severe hypertension.

77S SANTUCCI, A., AGUGLIA, F., DE MATTIA, G., FICARA, C. & BALSANO, F. Long-term captopril treatment in moderate to severe hypertension.

81S MIMRAN, ALBERT & JOVER, BERNARD Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage.

87S SILBERBAUER, K., STANEK, B. & TEMPL, H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.

95S PANEL DISCUSSION Inhibition of prostaglandin synthesis and captopril.

97S VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP ON ANTIHYPERTENSIVE AGENTS Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide.

103S RABINAD ESTRADA, E., INGELMO MORIN, M., MARTINEZ AMENOS, A., ALSINA, J. & BALCELLS GORINA, A. Captopril in essential hypertension.

107S ANDRÉN, LENNART, KARLBERG, BENGT, ÖHMAN, PETER, SVENSSON, ANDERS, ASPLUND, JOHAN & HASSON, LENNART Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.

113S PANEL DISCUSSION Selection of patients for treatment (including side effects of captopril).

117S FERNANDEZ-CRUZ, A. JR., LUQUE OTERO, M., FERNANDEZ PINILLA, C. & MARTELL CLAROS, N. Captopril in the treatment of mild essential hypertension.

121S STUMPE, K.O., OVERLACK, A., KOLLOCH, R. & SCHREYER, S. Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension.

127S WEINBERGER, MYRON H. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension.
133S KARLBERG, BENGT E., ASPLUND, JOHAN, WETTRE, STAFFAN, ÖHMAN, K. PETER, NILSSON, OVE R. Long-term experience of captopril in the treatment of primary (essential) hypertension.
139S PANEL DISCUSSION Long-term experience of captopril in the treatment of primary (essential) hypertension.

141S OAKLEY, G.M. Captopril—experience in heart failure—opening remarks.
143S KRAMER, BARRY, TOPIC, NINA & MASSIE, BARRY Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure.
153S WALSH, W.F. & LEE, C.L. Acute and chronic effects of captopril therapy in patients with refractory heart failure.
161S SHARPE, D.N. & COXON, R.J. Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure.
169S LEVINE, T. BARRY & COHN, JAY N. Factors predicting acute and long-term response to captopril therapy in congestive heart failure.
175S PANEL DISCUSSION Factors determining acute and long-term therapy response to captopril in congestive heart failure.
179S FAXON, DAVID P., CREAGER, MARK A. & HALPERIN, JONATHAN L. Regional circulatory response to converting-enzyme inhibition in congestive heart failure.
187S BOUNHOURE, J.P., KAYANAKIS, J.G., FAUVEL, J.M. & PUEL, J. Beneficial effects of captopril in left ventricular failure in patients with myocardial infarction.
193S LIEBAU, G., RIEGGER, A.J.G., SCHANZEUBÄCHER, P., STEILNER, H. & OEHRLEIN, S. Captopril in congestive heart failure.
201S PANEL DISCUSSION Response to captopril in congestive heart failure.
203S STEINGO, L., POCOCK, W.A., FLAX, H., STEIN, M. & BARLOW, J.B. Long-term captopril therapy in severe refractory congestive heart failure.
209S RICCI, S., ZANIOL, P., TEGLIO, V., BARALDI, P. & MATTIOLI, G. Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.
217S FITZGERALD, DESMOND, J., O'CALLAGHAN, WILLIAM G., O'MALLEY, KEVIN, HORGAN, JOHN & O'BRIEN, EOIN Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction.
223S KOMAJDA, M., EUGENE, M., EVANS, J., DROBINSKI, G., LAURENCEAU, J.L. & GROSGOGEAT, Y. Long-term treatment of congestive heart failure with captopril (SQ14, 225).
231S DAHLSTRÖM, ULF & KARLBERG, BENGT, E. Short- and long-term effects of treatment with low dose captopril in patients with severe congestive heart failure.
237S PANEL DISCUSSION The outcome of treatment in patients with severe heart failure.

241S ROUND TABLE DISCUSSION, PART I The role of captopril in the treatment of hypertension.
247S ROUND TABLE DISCUSSION, PART II The role of captopril in the treatment of heart failure.

VOLUME 14 NUMBER 1 JULY 1982

METHODS IN CLINICAL PHARMACOLOGY

15 BOYD, E.J.S. & WORMSLEY, K.G. Clinical assessment of antisecretory drugs in man.

METHODS IN CLINICAL TRIALS

25 GREENBERG, G. Logistics and management of clinical trials.

PAPERS

31 ORME, M.L'E. The Third S.K. & F. Prize Lecture. The clinical pharmacology of oral contraceptive steroids.

43 BACK, D.J., BRECKENRIDGE, A.M., MacIVER, M., ORME, M., ROWE, P.H. STAIGER, Ch., THOMAS, E. & TJIA, J. The effects of ampicillin on oral contraceptive steroids in women.

49 MILLAR, K. & STANDEN, P.J. Differences in performance impairment due to brompheniramine maleate as a function of the sustained-release system.

57 ADAM, KIRSTINE & OSWALD, I. A comparison of the effects of chlormezanone and nitrazepam on sleep.

67 HOUTZAGERS, J.J.R., STREURMAN, O. & REGÅRDH, C.G. The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol.

73 DANESHMEND, T.K. & ROBERTS, C.J.C. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol.

79 VON BAHR, CHRISTER, HERMANSSON, JÖRGEN & TAWARA, KAZUJI Plasma levels of (+) and (−)-propranolol and 4-hydroxypropranolol after administration of racemic (±)-propranolol in man.

83 HORNUNG, R.S., GOULD, B.A., KIESO, H.A. & RAFTERY, E.B. A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing.

89 ROWLANDS, D.B., GLOVER, D.R., STALLARD, T.J. & LITTLER, W.A. Control of blood pressure and reduction of echocardiographically assessed left ventricular mass with once-daily timolol.

SHORT REPORTS

97 HASSAN, S., MACDOUGALL, I.C., O'GRADY, J. & PICKLES, HILARY Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans.

99 CLIFFORD, J.M., DAY, M.D. & ORWIN, J.M. Reversal of clonidine induced miosis by the α_2-adrenoceptor antagonist RX 781094.

102 BAUMANN, P., TINGUELY, D. & SCHÖPF, J. Increase of acid α_1-acid glycoprotein after treatment with amitriptyline.

104 GABKA, J. & PRICE, R.K.J. Tooth pulp stimulation: a method of determining the analgesic efficacy of meptazinol in man.

107 ADITHAN, C. & THANGHAM, JOSEPH A comparative study of saliva and serum paracetamol levels using a simple spectrophotometric method.

110 MONIE, R.D.H., ROCCHICCIOLI, KAREN M. & WHITE, JANINE P. Sustained release theophylline in asthma and its interaction with rimiterol.

113 JENKINS, C.R., CHOW, C.M., FISHER, B.L. & MARLIN, G.E. Ipratropium bromide and fenoterol by aerosolized solution.

116 RITCH, A.E.S., PERERA, W.N.R. & JONES, C.J. Pharmacokinetics of azapropazone in the elderly.

120 KENDALL, M.J., QUARTERMAN, C.P., JACK, D.B. & BEELEY, L. Metoprolol pharmacokinetics and the oral contraceptive pill.

123 MORRISON, P.J., ROGERS, H.J., SPECTOR, R.G., BRADBROOK, I.D. & JOHN, V.A. Effect of pirprofen on glibenclamide kinetics and response.

127P PROCEEDINGS OF THE BRITISH PHARMACOLOGICAL SOCIETY. University of Strathclyde, Glasgow, 31st March, 1st–2nd April, 1982.

VOLUME 14 NUMBER 2 AUGUST 1982

METHODS IN CLINICAL PHARMACOLOGY

159 HODGSON, H.J.F. Assessment of drug therapy in inflammatory bowel disease.

METHODS IN CLINICAL TRIALS

171 VERE, D.W. Logic and inference in clinical trials.

PAPERS

177 PICKLES, HILARY & O'GRADY, J. Side effects occurring during administration of epoprostenol (prostacyclin, PGI_2) in man.
187 MIGNON, M., CHAU, N.P., NGUYEN-PHUOC, B.K., SAUVAGE, M., LEGUY, F. & BONFILS, S. Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships.
195 VAN HECKEN, A.M., TJANDRAMAGA, T.B., MULLIE, A., VERBESSELT, R. & DE SCHEPPER, P.J. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.
201 HOUGHTON, G.W., HUNDT, H.K.L., MULLER, F.O. & TEMPLETON, R. A comparison of the pharmacokinetics of metronidazole in man after oral administration of single doses of benzoylmetronidazole and metronidazole.
207 McGOWAN, W.A.W. & DUNDEE, J.W. The effect of intravenous cimetidine on the absorption of orally administered diazepam and lorazepam.
213 MAUDGAL, D.P., MAXWELL, J.D., LEES, L.J. & WILD, R.N. Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man.
219 BEGG, E.J., CHINWAH, P.M., WEBB, C., DAY, R.O. & WADE, D.N. Enhanced metabolism of mexiletine after phenytoin administration.
225 OCHS, HERMANN R., PABST, JOACHIM, GREENBLATT, DAVID J. & HARTLAPP, JOACHIM Digitoxin accumulation.
231 MWALUKO, GABRIEL & WEINSHILBOUM, RICHARD α-methyldopa, α-methyldopamine and α-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase.
241 SIMON, A. Ch., LEVENSON, J.A., LEVY, B.Y., BOUTHIER, J.E., PERONNEAU, P.P. & SAFAR, M.E. Effect of nitroglycerin on peripheral large arteries in hypertension.
247 KELMAN, ANDREW W., WHITING, BRIAN & BRYSON, SCOTT M. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics
257 JACKSON, P.R., RAMSAY, L.E. & WAKEFIELD, V. Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypolakaemia.
265 FREESTONE, S., SILAS, J.H. & RAMSAY, L.E. Sample size for short-term trials of antihypertensive drugs.
269 HONG, C.Y. & TURNER, P. Influence of lipid solubility on the sperm immobilizing effect of β-adrenoceptor blocking drugs.
273 DIXON, P.A., OFORAH, E. & MAKANJUOLA, R. Predictive indices for chlorpromazine therapy in schizophrenics.

SHORT REPORTS

279 RUBIN, PETER C., BUTTERS, LUCY, LOW, ROBERT A. & REID, JOHN L. Atenolol in the treatment of essential hypertension during pregnancy.
282 WILKINSON, P.R., TAIT, C., HESP, R. & RAFTERY, E.B. Potassium supplements during long-term thiazide therapy for essential hypertension.
284 MAGNUSSON, JAN OLOF, BERGDAHL, BJÖRN, BOGENTOFT, CONNY & JONSSON, ULF E. Metabolism of digoxin and absorption site.
286 ADAMS, K.R.H., HALLIDAY, L.D.C., SIBEON, R.G., BABER, N., LITTLER, T. & ORME, M. L'E. A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations.
290 PEDERSEN, S. Treatment of children with a single dose a day of sustained release theophylline.
292 HARENBERG, J., STAIGER, Ch., de VRIES, J.X., WALTER, E., WEBER, E. & ZIMMERMANN, R. Cimetidine does not increase the anticoagulant effect of

phenprocoumon.
294 PORRO, M.G., KUPFERBERG, H.J., PORTER, R.J., THEODORE, W.H. & NEWMARK, M.E. Phenytoin: an inhibitor and inducer of primidone metabolism in an epileptic patient.
298 PETERSON, GREGORY M., McLEAN, STUART, ALDOUS, STEPHEN, VON WITT, RICHARD J. & MILLIGEN, KEITH S. Plasma protein binding of phenytoin in 100 epileptic patients.
301 LENNARD, M.S., SILAS, J.H., FREESTONE, S. & TREVETHICK, J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
304 KELLY, J.G., McGARRY, C., O'MALLEY, K. & O'BRIEN, E.T. Bioavailability of labetalol increases with age.
306 ANDREASEN, F., BØTKER, H.E. & LORENTZEN, K. *In vitro* studies on the hydrolysis of frusemide in gastrointestinal juices.
310 BARNETT, D.B., HUDSON, S.A. & McBURNEY, A. Disopyramide and its n-monodesalkyl metabolite in breast milk.

VOLUME 14 NUMBER 3 SEPTEMBER 1982

page

METHODS IN CLINICAL PHARMACOLOGY

315 BURNHAM, W.R. Nutritional support of patients with gastrointestinal disease.

METHODS IN CLINICAL TRIALS

325 COX, D.R. Statistical significance tests.

PAPERS

333 WILSON, K., ORAM, MARCIA, HORTH, C.E. & BURNETT, D. The influence of the menstrual cycle on the metabolism and clearance of methaqualone.
341 ORAM, MARCIA, WILSON, K. & BURNETT, D. The influence of oral contraceptives on the metabolism of methaqualone in man.
347 MILLAR, J.R., DERKX, F.H.M., McLEAN, KATHLEEN & REID, J.L. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK 421 (enalapril) and MK 521.
357 ULM, E.H., HICHENS, M., GOMEZ, H.J., TILL, A.E., HAND, E., VASSIL, R.C., BIOLLAZ, J., BRUNNER, H.R. & SCHELLING, J.L. Enalapril maleate and a lysine analogue (MK 521): disposition in man.
363 BIOLLAZ, J., SCHELLING, J.L., JACOT DES COMBES, B., BRUNNER, D.B., DESPONDS, G., BRUNNER, H.R., ULM, E.H., HICHENS, M. & GOMEZ, H.J. Enalapril maleate and a lysine analogue (MK 521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.
369 HASSAN, S., PICKLES, HILARY, FISH, ALISON, BURKE, CHRISTINE, WARRINGTON, S. & O'GRADY, J. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI_2) are unaffected by β-adrenoceptor blockade in man.
379 RITTER, JAMES M., ORCHARD, MARGARET A. & LEWIS, PETER J. Inhibition of vascular epoprostenol (prostacyclin, PGI_2) production *in vitro* by plasma from healthy subjects and patients with severe renal impairment.
385 MATHER, LAURENCE A. & GLYNN, CHRISTOPHER J. The minimum effective analgetic blood concentration of pethidine in patients with intractable pain.
391 KOBZA BLACK, A., GREAVES, M.W. & HENSBY, C.N. The effect of systemic prednisolone on arachidonic acid and prostaglandin E_2 and $F_{2\alpha}$ levels in human cutaneous inflammation.
395 HOUSTON, J.B., DAY, J. & WALKER, J. Azo reduction of sulphasalazine in healthy volunteers.

399 MARTY, J.J., KILPATRICK, C.J. & MOULDS, R.F.W. Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.
405 DEW, M.J., HUGHES, P.J., LEE, M.G., EVANS, B.K. & RHODES, J. An oral preparation to release drugs in the human colon.
409 RHODES, J.C., AARONS, L.J. & HOUSTON, J.B. Interpretation of CO_2 exhalation rate data from demethylation of aminopyrine and its metabolite monomethylaminoantipyrine.
415 HORNUNG, R.S., GOULD, B.A., KIESO, H. & RAFTERY, E.B. The effect of a combination of timolol, hydrochlorothiazide and amiloride on 24 hour blood pressure control using ambulatory intra-arterial monitoring.
421 GUGLER, R., MÜLLER-LIEBENAU, B. & SOMOGYI, A. Altered disposition and availability of cimetidine in liver cirrhotic patients.
431 EL ALLAF, D., HENRARD, L., CROCHELET, L., DELAPIERRE, D., CARLIER, J. & DRESSE, A. Pharmacokinetics of mexiletine in renal insufficiency.
437 WATSON, I.D., COHEN, H.N., STEWART, M.J., McINTOSH, S.J., SHENKIN, A. & THOMSON, J.A. Comparative pharmacokinetics of co-trifamole and co-trimoxazole to 'steady state' in normal subjects.

SHORT REPORTS

445 FULLER, R.W. & VALLANCE, P.J.T. Atenolol reduces blood pressure and FEV_1 in normal subjects.
447 KAMPMANN, JENS P., SVENDSEN, TAGE LYSBO, SKOLSTED, LIS & MØLHOLM HANSEN, JENS E. β_2-adrenoceptor agonists and thyroid hormones.
449 McINNES, GORDON T., SHELTON, JOHN R., HARRISON, IAN R., PERKINS, RICHARD M. & RIGBY, GEORGE V. Diuretic induced hypokalaemia: relationship to dosage interval and plasma aldosterone.
453 DAWSON, M., ALLAN, R.J. & WATSON, T.R. The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [^{3}H]-mebendazole.
456 VIINIKKA, LASSE, TOIVANEN, JARMO & YLIKORKALA, OLAV The effect of prolonged treatment with sulphinpyrazone on thromboxane A_2 and prostacyclin in man.
459 RAE, SARAH A., WILLIAMS, I.A., ENGLISH, JUDITH & BAYLIS, E. MARY Alteration of plasma prednisolone levels by indomethacin and naproxen.

LETTERS TO THE EDITORS

463 THOMPSON, P.J., KEMP, M.W., McALLISTER, W. & TURNER WARWICK, M. The use of aminophylline by inhalation.
464 BLACK, J.L., SALOME, C.M., YAN, K. & SHAW, J. Comparison between airways response to an α-adrenoceptor agonist and histamine in asthmatic and non-asthmatic subjects.
466 BARRADAS, M.A., MIKHAILIDIS, A.M., MIKHAILIDIS, D.P. & DANDONA, P. The effects of fenfluramine on *in vitro* platelet aggregation.
468 NICHOLSON, F., CLARK, K.L., BRECKER, S.J.D. & SMITH, S.A. A pharmacological method for measuring the penetration of topical mydriatic drugs in man.

VOLUME 14 NUMBER 4 OCTOBER 1982

METHODS IN CLINICAL TRIALS

page
473 SIMON, RICHARD Patient subsets and variation in therapeutic efficacy.

PAPERS

483 ADELUSI, S.A., DAWODU, A.H. & SALAKO, L.A. Kinetics of the uptake and elimination of chloroquine in children with malaria.
489 CUISINAUD, G., FERRY, N., POZET, N., ZECH, P.Y. & SASSARD, J. Nalidixic acid kinetics in renal insufficiency.

495 ILIOPOULOU, A., ALDHOUS, M.E., JOHNSTON, A. & TURNER, P. Pharmacokinetic interaction between theophylline and erythromycin.
501 McKAY, J., RAWLINGS, M.D., COBDEN, I. & JAMES, O.F.W. The acute effects of ethanol on acetanilide disposition in normal subjects, and in patients with liver disease.
505 BERKIN, K.E. & KERR, J.W. Tiaramide—a new oral drug for the treatment of asthma.
509 BAYLEY, S., DOBBS, R.J. & ROBINSON, B.F. Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.
513 OLATUNDE, A. & PRICE EVANS, D.A. Blood quinidine levels and cardiac effects in white British and Nigerian subjects.
519 KUMANA, CYRUS R., RAMBIHAR, VIVIAN S., TANSER, PAUL H., CAIRNS, JOHN A., GUPTA, RAM N., WILDEMAN, RICHARD A., JOHNSTON, MARY, JOHNSON, ARNOLD L. & GENT, MICHAEL A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction.
529 KUMANA, CYRUS R., RAMBIHAR, VIVIAN S., WILLIS, KEN, GUPTA, RAM N., TANSER, PAUL H., CAIRNS, JOHN A., WILDEMAN, RICHARD A., JOHNSTON, MARY, JOHNSON, ARNOLD L. & GENT, MICHAEL Absorption and antidysrythmic activity of oral disopyramide phosphate after acute myocardial infarction.
539 SKJELBRED, P. & LØKKEN, P. Codeine added to paracetamol induced adverse effects but did not increase analgesia.
545 FILE, SANDRA A. & LISTER, RICHARD G. Do lorazepam-induced deficits in learning result from impaired rehearsal, reduced motivation or increased sedation?
551 LEE, J.N., CHEN, S.S., RICHENS, A., MENABAWEY, M. & CHARD, T. Serum protein binding of diazepam in maternal and foetal serum during pregnancy.
555 REDPATH, J.B.S. & PLEUVRY, B.J. Double-blind comparison of the respiratory and sedative effects of codeine phosphate and (±)-glaucine phosphate in human volunteers.

SHORT REPORTS

559 PLEUVRY, B.J. & REDPATH, J.S. Ventilatory and cardiovascular effects of BHT 933 in volunteers.
562 ELLIOTT CHAM, B., DYKMAN, JAAP H.M. & BOCHNER, FELIX Urinary excretion of aspirin.

LETTERS TO THE EDITORS

565 PEDEN, N.R. & WORMSLEY, K.G. Effect of cimetidine on gonadal function in man.
565 HARDELL, LARS-IVAR, LINDSTRÖM, BJÖRN, LÖNDERHOLM, GUDMAR & OSTERMAN, PER OLOF Pyridostigmine in human breast milk.
567 LENNARD, L., BROWN, C.B., FOX, M. & MADDOCKS, J.L. Azathioprine dosage schedule and rejection episodes in renal transplant recipients.
571P PROCEEDINGS OF THE SCANDINAVIAN AND BRITISH PHARMACOLOGICAL SOCIETIES Stockholm, Sweden, 5th-6th July, 1982.

VOLUME 14 NUMBER 5 NOVEMBER 1982

METHODS IN CLINICAL PHARMACOLOGY

page
631 PARK, B.K. Assessment of the drug metabolism capacity of the liver.

METHODS IN CLINICAL TRIALS

653 EVANS, S.J.W. What can we do with the data we throw away?

CONTROVERSIES IN CLINICAL PHARMACOLOGY

661 O'MALLEY, K. & O'HANRAHAN, M. Drug promotion and the doctor.
664 SNELL, E.S. Drug promotion and the doctor—A reply.

PAPERS

667 STEELE, W.H., HAWKSWORTH, G.M. & BARBER, H.E. The binding of prednisolone in human serum and to recrystallised human albumin *in vitro*.

673 BREDESEN, JAN ERIK, PIKE, EVA & LUNDE, PER KNUT M. Plasma binding of disopyramide and mono-*N*–dealkyldisopyramide.

677 DARRAGH, AUSTIN, LAMBE, RONAN, KENNY, MARIE, BRICK, IAN, TAAFFE, WILLIAM & O'BOYLE, CIARAN Ro 15–1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.

683 NICHOLSON, A.N., SMITH, P.A. & SPENCER, M.B. Antihistamines and visual function: studies on dynamic acuity and the pupillary response to light.

691 SCOTT, D.L., RODEN, S., MARSHALL, T. & KENDALL, M.J. Variations in responses to non-steroidal anti-inflammatory drugs.

695 RILEY, ALAN J., RILEY, ELIZABETH J. & DAVIES, H.J. A method for monitoring drug effects on male sexual response: the effect of single dose labetalol.

701 FISKEN, ROGER A., WILKINSON, ROBERT & HEATH, DAVID A. The effects of cimetidine on serum calcium and parathyroid hormone levels in primary hyperparathyroidism.

707 BUTLAND, R.J.A., PANG, J.A. & GEDDES, D.M. The selectivity of the β-adrenoceptor for ventilation in man.

713 FREESTONE, S., SILAS, J.H., LENNARD, M.S. & RAMSAY, L.E. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.

719 FERGUSON, ROGER K., VLASSES, PETER H., KOPLIN, JANICE R., HOLMES, GEOFFREY I., HUBER, PAUL, DEMETRIADES, JOAN & ABRAMS, WILLIAM B. Relationships among timolol doses, plasma concentrations and β-adrenoceptor blocking activity.

727 NICHOLLS, D.P., HARRON, D.W.G., McAINSH, J., CASTLE, W.M., BARKER, N.P. & SHANKS, R.G. Comparative pharmacological and pharmacokinetic observations on propranolol (long-acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

733 VANDENBURG, MALCOLM J. The acute and chronic effect of oxprenolol and propranolol on peripheral blood flow in hypertensive patients.

SHORT REPORT

739 GOUGH, PATRICIA A., CURRY, STEPHEN H., ARAUJO, OSCAR E., ROBINSON, J. DANIEL & DALLMAN, JOHN J. Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive damage.

LETTERS TO THE EDITORS

743 TUCKER, G.T., BAX, N.D.S., LENNARD, M.S., CREWE, K. & WOODS, H.F. Lack of effect of atenolol on antipyrine clearance.

744 CALDARA, ROBERTO, RAMPINI, PIETRO, PIEPOLI, VALERIA & BORZIO, MAURO Effect of labetalol on α- and β-adrenoceptor antagonist, on gastric acid and gastrin secretion in man.

746 HERZOG, P., HOLTERMÜLLER, K.H., KASPER, W., MEINERTZ, T., TRENK, D. & JAHNCHEN, E. Absorption of mexiletine after treatment with gastric antacids.

748 DOWELL, P.S., PIERCE, D.M., FRANKLKIN, R.A., ROBSON, P.J. & JACKSON, M.B.A. Routes of meptazinol conjugation in the neonate.

750 STEVENS, MAXINE J., LIPE, SUZANNE & MOULDS, ROBERT F.W. The effect of age on the responses of human isolated arteries and veins to noradrenaline.

752 GIACOMINI, KATHLEEN M., ABANG, ANTHONY & BLASCHKE, TERRENCE F. Calculation of drug concentration in plasma after equilibrium dialysis.

754 KECHEJIAN, HAGOP The clinical assessment of analgesic drugs.

VOLUME 14 NUMBER 6 DECEMBER 1982

page

METHODS IN CLINICAL PHARMACOLOGY

757 TROTMAN, IVAN & MISIEWICZ, GEORGE Methods in human alimentary motility.

METHODS IN CLINICAL TRIALS

765 SPICER, C.C. Statistical decision theory and clinical trials.

PAPERS

769 ROVEI, V., CHANOINE, F. & STROLIN BENEDETTI, M. Pharmacokinetics of theophylline: a dose-range study.

779 BASHIR, A., LEWIS, M.J. & HENDERSON, A.H. Pharmacokinetics studies of various preparations of glyceryl trinitrate.

785 RAGHURAM, T.C. & KRISHNASWAMY, K. Pharmacokinetics and plasma steady state levels of doxycycline in undernutrition.

791 HAMILTON, M.J., BUSH, M., SMITH, P. & PECK, A.W. The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.

799 SCHMIDLIN, O., GUNDERT-REMY, U., MÄURER, W. & WEBER, E. Differences of sympathomimetic and anticholinergic action of OH-maprotiline and its R (−)-enantiomer.

805 ROBINSON, J.F. & DOOGAN, D.P. A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers.

809 MOJAVERIAN, PARVIZ, FEDDER, IRA L., VLASSES, PETER H., ROTMENSCH, HESCH H., ROCCI, MARIO L.Jr., SWANSON, BRIAN N. & FERGUSON, ROGER K. Cimetidine does not alter morphine disposition in man.

815 JÖNSSON, K-Å., ERIKSSON, S-E., KAGEVI, I., NORLANDER, B., BODEMAR, G. & WALAN, A. Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose.

821 KENDALL, M.J., WOODS, K.L., WILKINS, M.R. & WORTHINGTON, D.J. Responsiveness to β-adrenergic receptor stimulation: the effects of age are cardioselective.

827 GOULD, B.A., HORNUNG, R.S., KIESO, H., MANN, S. & RAFTERY, E.B. The effect of once daily β-adrenoceptor blocker—thiazide diuretic combination on the ambulatory blood pressure.

833 STEINER, J.A., COOPER, R., McPHERSON, K. & RILEY, A.J. Effect of β-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients.

839 DART, A.M., McHARDY, K. & BARBER, H.E. The effect of propranolol on luteinising hormone and prolactin concentrations in hypertensive women.

843 STRUTHERS, A.D., WHITING, B., HILLIS, W.S. & KELMAN, A.W. The effect of glyceryl trinitrate ointment on heart rate – corrected systolic time intervals in angina pectoris.

849 STURANI, A., CHIARANI, C., DEGLI ESPOSTI, E., SANTORO, A., ZUCCALA, A. & ZUCCHELLI, P. Heart rate control in hypertensive patients treated by captopril.

857 HENDERSON, I.S., BEATTIE, T.J., KENNEDY, A.C. & DOMBEY, S.L. Oral piretanide in chronic renal failure.

861 MORELAND, T.A., PARK, B.K. & RYLANCE, G.W. Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6β-hydroxycortisol excretion and plasma γ-glutamyltranspeptidase activity.

SHORT REPORT

867 HOUBEN, H., THIEN, Th., WIJNANDS, G. & VAN 't LAAR, A. Effects of cold exposure on blood pressure, heart rate and forearm blood flow in normotensives during selective and non-selective β-adrenoceptor blockade.

LETTERS TO THE EDITORS

871 DARRAGH, AUSTIN, LAMBE, RONAN, BRICK, IAN & O'BOYLE, CIARAN Antagonism of the central effects of 3-methylclonazepam.